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The Role of Sex Hormones on Monocarboxylate Transporter Expression in Tissues Related to
Drug Disposition

Abstract

By Jieyun Cao
University of the Pacific
2018

Proton- and sodium-dependent monocarboxylate transporters (MCTs (SLC16A) and
SMCTs (SLC5A)) transport monocarboxylates such as ketone bodies, lactate and pyruvate, as
well as drugs such as gamma-hydroxybutyric acid. CD147 acts as an ancillary protein for MCT1
and MCT4, and is involved in membrane trafficking. Previously, it has been shown that MCT
expression changes under different sex hormone conditions in skeletal muscle and Sertoli cells.
However, it is unknown if MCTs, SMCTs or CD147 demonstrate sex differences in tissues
where they play an important role in drug disposition. Monocarboxylate transporter substrates
GHB and valproic acid have demonstrated sex differences in pharmacokinetic profiles. We
hypothesize that sex hormones regulate monocarboxylate transporters and CD147 expression in
drug disposition tissues, including the liver, intestine and kidney.
The purpose of the current study is to evaluate sex and sex hormone dependent regulation
of MCT1, MCT4, SMCT1 and CD147 mRNA and protein expression in drug disposition tissues.
Liver, kidney and intestinal segments (duodenum, jejunum and ileum) were harvested from
estrus cycle staged female rats, ovariectomized (OVX) females, males and castrated (CST) male
rats. Hormone replacement experiments were performed to investigate testosterone and 17βestradiol dependent regulation of renal MCTs, SMCT1 and CD147 in OVX females and CST
males. mRNA of MCT1, MCT4, SMCT1 and CD147 was evaluated by real time quantitative
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PCR. Whole cell protein and membrane protein was extracted, target protein expression was
evaluated by western blot.
We have demonstrated sex and sex hormone dependent regulation of MCT1, MCT4,
SMCT1 and CD147 in the liver, intestine regions and kidney occurs in a tissue specific manner.
mRNA, protein expression and membrane localization of monocarboxylate transporters and
CD147 were regulated differently by sex hormones. Sex differences in MCTs and SMCTs
expression are important determinants of drug disposition in the body and sex differences in their
regulation may contribute to differences in drug pharmacokinetics.
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Chapter 1: Introduction

Transporters are membrane proteins that are important to the distribution of both
endogenous and exogenous compounds. They play a vital role in uptake, distribution, excretion
of nutrients, peptides, sugars, hormones and drugs. There are different types of transporters
based on sequence homology, including solute carrier families, water channels, ATP-binding
cassette transporters and ion channels. Among these, the solute carrier super family (SLC) is the
largest group of transporters consisting of 53 subfamilies with 456 members discovered thus far
[3]. SLC transporters are also the second largest membrane protein family in the human genome
after the G-protein-coupled receptors [4, 5]. The SLC families include passive transporters,
exchangers and ion transporters. These transporters are functionally related in that, with a few
exceptions, they do not need energy to transport substrates across the cellular membrane. SLC
function depends on ion gradients across the cell membrane as the driving force to move the
substrates to desired side of the membrane [4, 6].
Monocarboxylate transporters belongs to the SLC super family: proton-coupled
monocarboxylate transporters (MCTs) are encoded by SLC16A and sodium coupled
monocarboxylate transporters (SMCTs) are encoded by SLC5A. MCTs and SMCTs are named
after their substrate specificity for monocarboxylate short chain fatty acids. There is no sequence
homology between these two families [7].
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1.1 Proton- dependent Monocarboxylate Transporters
There are 14 members in the proton-coupled monocarboxylate transporter family in
humans encoded by SLC16A genes [8, 9]. The family is known as the monocarboxylate
transporter (MCT) family since the first members to be identified were the proteins responsible
for the proton-linked transport of important monocarboxylate metabolites [10]. While MCTs are
named monocarboxylate transporters, only five of the family members have been shown to
transport monocarboxylates. MCT1, MCT2, MCT3 and MCT4 have been demonstrated to
transport short chain acids including pyruvate, acetate, lactate and other carboxylate acids.
Recently, it has been shown that MCT7 (SLC16A6) functions as ketone body transporter, with
efflux of ketone bodies out of hepatocytes into the blood stream during fasting in zebrafish [11].
Transport of substrates by MCTs is birdirectional, is coupled with a proton and driven by proton
gradients instead of ATP.
MCT1 was the first identified member of the MCT family and as such this isoform has
been the most extensively characterized in terms of structure and function. Through hydropathy
plots, MCT1 is predicted to consist of 12 transmembrane helices, with a C- and N- termini within
the cellular membrane (Figure 1.1) [12]. There is a large intracellular loop between
transmembrane domain 6 and 7 ranging from 29 to 105 amino acid for different MCTs. The
greatest variation among the isoforms beside the large intracellular loop is the C termini. The
variation is believed to lead to differences in transporter regulation, localization and substrate
variation [9, 12]. This proposed topology of the transporter is thought to be shared with all the
other members of MCT family based on sequence similarities.
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Figure 1.1: Monocarboxylate Transporter 1 and ancillary protein CD147 structure
illustration (from [12]).

Figure 1.2 illustrates tissue expression of MCT1, MCT2 and MCT4 in humans [13].
MCT1 is ubiquitously expressed in the majority of organs with no variation in tissue distribution
among species [12, 13]. It is expressed in tissues such as liver, kidney, brain, GI tract, muscle
and red blood cells in humans. MCT2 has a relatively limited expression compared to MCT1 in
human tissues, and is mostly expressed in kidney, liver, testis, heart and skeletal muscles [14,
15]. Similar MCT2 expression patterns have been observed in rast, mice and hamsters [14, 15].
MCT2 appears to be important for brain energy supply [9, 16]. MCT3 is mostly expressed in the
retinal pigment epithelium (RPE) and choroid plexus and is restricted to the basolateral
membrane [17, 18]. Protein expression has also been detected in human smooth muscle cellsand
Caco-2 cell line, with mRNA expression observed in HK-2 cells [19-21]. MCT4 demonstrates a
similar tissue distribution to MCT1 including white muscle cells, RPE, kidney, heart and brain
[9]. Even though MCT1 – MCT4 are detected in the kidney, they localize in different parts of
the nephron. MCT1 is expressed on the basolateral side of kidney proximal tubule epithelial
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cells, while MCT2 is localized to the thick ascending limb of the Loop of Henle and the distal
convoluted tubule [15, 22]. MCT4 is expressed on basolateral membrane kidney proximal
tubule epithelial cells [23].

Figure 1.2: Proton- coupled monocarboxylate transporter (MCT) distribution in
human body (from [13]).

To actively transport substrates across the plasma membrane, an ancillary protein is
essential for MCT1 – 4 [23-25]. CD147 (basigin) plays vital role as the ancillary protein for
MCT1, MCT3 and MCT4 [23, 24]. CD147 is a glycoprotein with one transmembrane domain
[26]. Formation of MCT/CD147 heterodimer in the endoplasmic reticulum is important for
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efficient trafficking of the transporters to plasma membrane (Figure 1.1) [17, 24]. In the absence
of CD147, MCTs fail to translocate to the cellular membrane and accumulate in the cytosol in
COS7, HeLa and RBL.2H3 cells [25]. The binding and formation of the transporter-ancillary
protein heterodimer was confirmed by fluorescence resonance energy transfer (FRET) and coimmunoprecipitation [27]. Embigin (gp70) is required for MCT2 translocation to the plasma
membrane [25]. MCT1 preferentially binds to CD147 for membrane trafficking; however, when
CD147 is absent, MCT1 also binds to Embigin [25]. So far, this alternate binding to Embigin
has not been observed with the other two MCTs that interact with CD147: MCT3 and MCT4
[10]. Altered regulation of CD147 has been shown to occur in many disease states, such as
cancer and infectious diseases [26]. Some of the diseases are associated with an alteration in the
interaction between CD147 and MCTs.
1.2 Sodium-dependent Monocarboxylate Transporters
Two members of the SMCT family have been discovered: SMCT1 (SLC5A8) and
SMCT2 (SLC5A12). The putative structure of SMCT1 and SMCT2 are similar. They both have
13 transmembrane domains with the N and C termini on opposite sides of cellular membrane
[28]. The 3D structure was predicted based on sequence homology of a previously characterized
membrane transporter, the Vibrio parahaemolyticus sodium/galactose symporter [28, 29].
Unlike MCTs more ubiquitous distribution in the body, SMCTs distribute mainly in kidney and
intestine [30]. SMCT1 was first discovered in the kidney, and subsequently expression was
observed in the human intestine, salivary gland, thyroid gland, brain, and retina, and mouse brain
[31-33]. SMCT2 mRNA expression is found in human kidney, small intestine, skeletal muscle
and very limited expression in the brain and retina [34]. SMCT1 is localized to the S3 segment
of proximal tubule, while SMCT2 spread on the entire length of the proximal tubule in kidney
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[34]. SMCTs are expressed on the apical membrane in kidney epithelia and intestinal
enterocytes. Substrates of SMCTs are similar to MCTs, but transport is coupled with sodium
ions, in ratios between 4:1 and 2:1(Na: substrate) [31, 35].
1.3 Regulation of MCTs and SMCTs
1.3.1 Factors regulating MCTs and SMCTs. Monocarboxylate transporter expression
can be regulated by many factors, such as substrate exposure, age, exercise and obesity [10, 3638]. In the colonic cell line AA/C1, MCT1 mRNA and membrane protein expression increased
upon exposure to its substrate butyrate [36]. The increase in expression level was concentration
and time dependent [36]. Regulation of MCT1 expression by lactate has also been demonstrated
in L6 cells [39] . Similarly, a ketogenic diet (high fat diet with 91% fat and 9% protein) lead to
an elevated plasma monocarboxylate concentration and upregulation of membrane MCT1
protein expression in the brain endothelial cells of adult male rats [40]. Food deprivation, on the
other hand, has been shown to alter MCT2 expression, but not MCT1 in the postrema-solitary
tract nucleus (AP-NTS) region of the brain in female Wistar rats [41]. In female rats, 48-hour
food deprivation upregulated MCT2 mRNA expression, but MCT1 did not show differences in
the brain [41]. This result suggests that the regulatory pathways differ between MCTs [41].
Monocarboxylate transporter expression varies during development. MCT1 mRNA
expression peaks at post-natal day 15 during mouse brain development and declined rapidly by
post-natal day 30 [37]. MCT2 showed a similar developmental pattern to MCT1 in mouse brain
[37]. Despite the similarity in age-dependent mRNA expression, MCT1 and MCT2 showed
different distribution in the brain [37]. The MCT1 transcript was expressed more prominently in
the cerebellum while MCT2 expression was comparable in the cortex, the hippocampus and the
cerebellum regions [37]. Age differences in MCT protein expression were also observed.
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Suckling rats at post-natal day 17 had 25 times greater MCT1 protein expression than adult rats
in the cerebral cortex endothelial cells [42]. Currently there is limited information on
developmental expression of MCTs and SMCTs in other tissues.
Exercise and obesity have been demonstrated to alter MCT expression. Endurance
training decreases MCT1 protein expression in breast cancer baring female BALB/c mice with a
concomitant decrease in CD147 expression [38]. MCT4 was not altered by this endurance
training. The author also indicated that the observed decrease in MCT1 protein expression could
be associated with inhibition of oestrogen-related receptor alpha [38]. Alteration in MCT
expression by exercise have been observed in human muscle. After 4 weeks of sprint-interval
training, women showed increased MCT1 muscle protein expression [43]. Obesity can regulate
MCTs expression as well. MCT1, MCT2 and MCT4 protein expression was increased in the
brain after 12 weeks of high fat diet in mice [44] with similar increases observed in the
genetically obese or diabetic mice [44]. Maternal obesity was shown to lead to increased MCT1
protein expression in the skeletal muscle of the offspring rats [45]. Elevated MCT4 protein
expression was observed in human obese subjects [46]. In addition, heterozygous MCT1 knock
out mice appeared to be resistant to obesity when fed with high sugar and high fat diet compared
to wild type [47].
1.3.2 Hormonal regulation of MCTs and SMCTs. Literature data demonstrates that
some MCT substrates display sex differences in systemic concentrations in both human and
rodents. Cupeiro et al. (2012) demonstrated that males have higher plasma lactate levels
following exercise [48]. This sex difference could be the result of differences in transporter
capacity. In a study of valproic acid pharmacokinetics, women had higher peak plasma
concentrations compared to men, unless they were on hormonal birth control (Figure 1.3) [49].
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This sex difference in valproic acid pharmacokinetics may be due to sex differences in
transporter regulation. Preliminary data in our laboratory suggested that GHB toxicokinetic and
renal clearance varied over the estrus cycle (data not shown), likely due to underlying changes in
monocarboxylate transporter expression in the kidney.

Figure 1.3: Valproic acid plasma concentrations varied between sexes (from [49]).

Previously, there are studies demonstrating that MCT expression is regulated by sex
hormone in various tissues. Enoki et al. (2006) reported that testosterone increases skeletal
muscle MCT1 and MCT4 whole protein expression. However, the induction was tissue specific
as there was no change in MCT1 expression in the heart [50]. Additionally, in 17 beta-estradiol
or dihydrotestosterone treated rat Sertoli cells, there was decreased MCT4 mRNA levels [51].
Hypophysectomized rats showed increased testicular MCT2 mRNA expression [52].
Testosterone mediated regulation of MCT2 was further confirmed by both in vivo and in vitro
testosterone treatment resulting in a reduction in MCT2 mRNA expression [52]. Inhibition of
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oestrogen-related receptor alpha decreased MCT1 expression in breast cancer tumor baring mice
[38]. In ovariectomized mice, progesterone decreased SMCT1 protein expression with no
change in mRNA level in kidney [53]. Contrastingly, orchiectomized mice treated with
testosterone had elevated SMCT1 mRNA and protein level [54]. These studies suggest that
MCTs and SMCTs are regulated by sex hormones in a tissue specific manner.
Despite literature reports indicating MCTs/ SMCTs expression can be regulated by sex
hormones, there is a lack of data on sex differences drug distribution tissues. Organs such as
intestine, liver and kidney play a vital role in drug absorption, distribution, metabolism and
elimination (ADME). The intestine is in involved in drug and nutrient absorption. The liver
plays an important role in drug biotransformation and clearance. The kidneys, through the
physiological processes of filtration, secretion and reabsorption, play a vital role in body fluid
homeostasis, elimination of waste products, retention of key nutrients, and elimination of drugs
[55]. Active renal reabsorption, and intestinal and hepatic uptake of essential nutrients such as
lactate, pyruvate, butyrate and ketone bodies are mediated by monocarboxylate transporters.
These transporters are also involved in the transport pharmaceutical agents, including nicotinate,
valproic acid, nateglinide, salicylate, atorvastatin and GHB [10, 56]. It is of vital importance to
characterize function and regulation of monocarboxylate transporters in tissues involved in drug
distribution to further understand sex differences in drug pharmacokinetics.
1.3.3 Hormonal regulation of other drug transporters. Monocarboxylate transporters
are not the only kind of transporters that have been demonstrated to have sex differences and sex
hormone regulation of expression. One of the representative efflux proteins is p-glycoprotein (Pgp). It is an ATP -binding cassette protein that pumps drugs and xenobiotics out of the cells. Pgp protein expression showed sex differences in the rat intestine after food intake [57]. For
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female rats, the intestinal segments including duodenum, jejunum and ileum showed increased
protein expression after food intake [57]. Males, on the other hand, showed decreased P-gp
expression after food ingestion [57]. It was also observed that intestinal P-gp protein and mRNA
levels are higher in males compared female rats [57]. Oral administration of PEG 400,
previously believed inert, decreased mRNA levels of intestinal P-gp in males, but did not have
an effect in female groups [58]. However, there are other studies that show contradictory results
in Wistar rats: Wistar males showed lower P-gp protein expression levels in duodenum, jejunum
and ileum segments as compared to females [59] indicating the potential for strain differences in
sex hormone-dependent regulation. In vitro studies revealed that individual sex hormones
regulate P-gp differently. Estrone, estriol, and ethynyl estradiol elevated P-gp transporter levels
in kidney cell line LLC-PK1, while progesterone, estradiol, and norethisterone did not [60].
There is very limited data on the impact of estrus cycle stages on transporter expression in
females; however, one in vivo study demonstrated that mouse P-gp mRNA expression varied at
different estrus stages in a tissue specific manner [61], but protein expression was not evaluated.
Sex differences have been observed with other members of the SLC super family.
Organic anion transporters (OAT1 and OAT2) and organic cation transporter 2 (OCT2) are
representative uptake transporters which belong to the SLC 22 transporter family [62]. They can
be found in many tissues, such as kidneys and brain, and play an important role in the uptake of
small organic anion and cation molecules into the cytoplasm. Western blotting and
immunostaining showed that female OAT1 expression is lower compared to male Wistar rats
[63, 64]. Ljubojevic et al. (2004) demonstrated that renal OAT1 membrane expression was
downregulated by castration in male rats with the downregulation alleviated by testosterone
treatment [63]. Further, they reported that ovariectomy slightly upregulated the membrane

25

expression, and replacement of estradiol largely decreased the membrane protein expression of
OAT1 [63]. OCT2 was demonstrated to be regulated by sex hormones in Wistar rat kidney.
Administration of testosterone increased both mRNA and protein expression of OCT2 in rats in
both male and female [65]. Treatment of estradiol slightly decreased rat OCT2 expression [65].
However, it was reported that this sex-dependent regulation showed species differences. mRNA
of OCT2 in rabbit kidney was expressed more in male than female rabbits; however, the protein
and transport function did not show sex differences in rabbit [66].
There is evidence suggesting that nutrient transporters are regulated by sex hormones and
show sex differences. L-type amino acid transporter 1 (LAT1) appeared to be different between
the male and female zebra finch [67]. At post hatch day 30, zebra finch had higher LAT1
expression in certain area of the brain in males [67]. Facilitative glucose transporters (GLUT)
belong to the SLC super family and mediate glucose uptake throughout the body [68]. This
nutrient transporter was observed to have sex dependent expression. In the hypothalamus of
Wistar rats, Slc2a1 (Glut1) mRNA level was lower in male adolescent rats than female rats. For
Slc2a4 (Glut4), mRNA level was increased in male but not in female groups [69]. Liver and
kidney mRNA expression of Glut9 in mice was observed to be different between sexes. The
mRNA level of Glut9 was female predominant in the liver of adult mice, suggesting that the
difference is related to the presence of sex hormones after puberty [70]. Females retain the
expression level and males showed decreased transcripts level after they reach the peak at postnatal day 22 [70]. Glut3 did not exhibit sex differences between male and female placentas
under normal conditions; however, Glut3 mRNA expression increased in response to high fat
diet for male placentas, but not female placentas [71]. Sodium-coupled neutral amino acid
transporters (SNAT) are an important nutrient transporter expressed in many organs [72].
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SNAT2 in male placentas also respond to high fat diet with an elevated SNAT2 transcript level,
whereas female placentas showed no response to diet change [71]. These results suggest that the
observed sex differences are sex hormone-independent.
1.4 Nutrient and Drug Distribution
Monocarboxylate transporters play an important role in nutrient transport. Lactate is the
product of oxygen independent glycolysis. It can be used as an important energy source in cells
lacking oxygen. The transport and exchange of lactate between cells is mediated by
monocarboxylate transporters [37], and it is important for mammalian cells to maintain lactate
shuttling across the plasma membrane. Immediate efflux of lactic acid is needed for many
glycolytic cell types, such as white muscle cells, lymphocytes and other cell types in hypoxic
conditions [12]. Uptake of lactic acid is essential for cells in the brain, heart and red muscle cells
for cellular respiration, and is important for gluconeogenesis in liver and kidney cells. Lactate
shuttling is present in the brain where astrocytes go through glycolysis and produce lactate acid
[73]. Lactate is then effluxed by either MCT1 or MCT4 and taken up into the cell by MCT1 or
MCT2 [73, 74]. This lactate shuttling process can be found in many tissues and conditions, such
as between skeletal muscle tissues, photoreceptor cells and surrounding cells, hypoxic tumor
cells and perivascular tumor cells [75-78]. Monocarboxylate transporters are essential for
survival as evidenced by embryonic lethality observed in MCT1 knockout mice [79].
Monocarboxylates become the major nutrient supply during long term starvation as
monocarboxylates levels are elevated in the blood. Another example of MCT nutrient transport
is ketone bodies. Ketone bodies often circulate in the body as energy resources [80]. It is also a
factor that affects body pH since excess ketone formation cannot be utilized leading to
ketoacidosis [81]. Changes in body pH can affect the transport kinetics of MCT substrates as
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they are dependent on a pH gradient [56]. MCT transportation of ketone bodies, on the other
hand, helps to maintain a stable pH environment.
Their wide tissue distribution allows MCTs to enable metabolic relocation of substrates,
such as lactate, pyruvate and ketone bodies. These nutrients and energy supplies can be
produced in one location and exported by MCTs, followed by uptake into another tissue for
utilization as an energy source. Transporters that are expressed in the intestine, such as MCT1
and SMCT1, are responsible for absorbing short chain monocarboxylic acids such as butyrate,
propionate and acetate which are produced in the intestinal lumen [82, 83]. These nutrients are
used in the liver as substrates for lipogenesis and gluconeogenesis [11, 84, 85]. Transporters in
the kidney are responsible for reabsorption of nutrients from proximal tubule [20].
Monocarboxylate transporter subtypes that are expressed in different tissue and cell types
cooperate to maintain the homeostasis of nutrient shuttling and utilization [86].
Monocarboxylate transporters are important, not only for their role in nutrient
transportation, but for their pharmacological significance. In addition to the intrinsic
monocarboxylate bio-metabolites mentioned above, many drugs with a carboxylate group have
been shown to be substrates of these transporters, including nicotinate, valproic acid, nateglinide,
salicylate, atorvastatin, and GHB [87-90]. GHB is one of the most well-studied drug substrates
demonstrating capacity-limited renal clearance mediated by monocarboxylate transporters [20].
GHB tissue disposition is mediated by MCTs and SMCTs in many organs [91]. MCTs mediated
intestinal absorption of GHB has been observed both in vitro and in vivo [92]. MCTs are also
evidenced to be responsible for brain GHB uptake [93, 94]. It has been demonstrated that GHB
renal clearance is affected by both MCT and SMCT-mediated reabsorption in the kidney [20,
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95]. Lovastatin acid is reported to be absorbed by MCT4 in cultured mesangial cells. Salicylate
and valproic acid have been observed to be distributed by monocarboxylate transporters [12, 96].
1.5 Dissertation Objectives
Monocarboxylate transporter expression has been shown to be sex dependent in heart,
skeletal muscles and Sertoli cells [50, 51]. However, there are very limited studies evaluating
whether expression is regulated by sex hormones in tissues that are important for drug
disposition, including the liver, kidney and intestine. These organs are the major determinants of
drug absorption and clearance. Sex hormone-dependent variation in transporter expression in
these tissues would impact drug pharmacokinetics and systemic drug concentrations. Altered
drug disposition may lead to either insufficient plasma concentrations to obtain therapeutic
benefit or increased plasma concentrations leading to toxicity. Females are commonly excluded
in preclinical and in vitro studies, which may lead us to overlook sex differences in drug
disposition pathways.
The overall objective of this dissertation is to elucidate the role of hormonal regulation in
monocarboxylate transporter expression in tissues contributing to drug disposition. Based on
literature studies evaluating differences in monocarboxylate transporter substrate plasma
concentrations and clearance, we hypothesis that monocarboxylate transporters and their
ancillary proteins exhibit sex differences in drug distribution tissues including the liver, kidney,
and intestine due to differential exposure to sex hormones. To evaluate this hypothesis, we will
quantitatively evaluate MCTs, SMCTs and the ancillary protein CD147 mRNA expression, total
cellular and membrane protein expression in rat drug disposition tissues in males, over the estrus
cycle in females, ovariectomized females, and castrated males. Further, we will evaluate the
impact of estrogen and testosterone replacement on MCT/SMCT expression in the kidney.
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Chapter 2: Method Development and Trouble Shooting

2.1 Animals, Estrus Staging and Tissue Collection
2.1.1 Animals and tissue collection. Male and female Sprague Dawley (SD) rats,
ovariectomized females and castrated males were obtained from Envigo (liver and intestine) o
Charles River (kidney) at 8 weeks of age and were housed in a temperature-controlled room with
a 12-hour day/night lighting cycle. Room temperature were at 25 °C with steady humidity. All
rats were fed standard rat chow and water ad libitum. Animals were acclimatized for at least one
week before experiments. All experiments were approved by the Institutional Animal Care and
Use Committee at the University of the Pacific.
Vaginal lavage was performed immediately before sacrificing to confirm females’ estrus
stage, and each estrus stage evaluated represents an independent group of animals. Liver,
intestine and kidney samples were collected (3 – 5 per group) from all animals at 10 weeks of
age following exsanguination under isoflurane anesthesia between 10 am to 12 pm. Agematched ovariectomized female samples were collected two weeks post-surgery. Liver and
intestine samples were collected from animals obtained from Envigo; kidney samples were
collected in a separate study using animals obtained from Charles River. Tissue samples were
immediately snap frozen in liquid nitrogen and stored at -80°C until analysis.
2.1.2 Estrus cycle stages. Female hormones fluctuate during the reproductive cycle and
regulate reoccurring physiological changes in adulthood. The rodent estrus cycle is composed of
four stages: proestrus, estrus, metestrus and diestrus. For female rats, the estrus cycle usually
lasts about 4 to 5 days [97, 98]. Proestrus, estrus and metestrus stages are relatively short
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compared to the diestrus stage. The three stages are normally one day long each, while diestrus
varies between one to two days. In some cases, female rat diestrus stage can last as long as three
days. In this case, estrus cycle last 6 days. The alterations in circulating levels of female sex
hormones change the cytology of the vaginal canal. Evaluating the cytology of vaginal smears
has been an effective method for accessing rodent reproductive cycles [97, 99].
The estrus stage of female rats was monitored daily by vaginal lavage smear for 8 – 12
days (at least two estrus cycle) between 10 am and 12 pm. Female rats were anaesthetized using
isoflurane anesthesia (3% – 4% induction and 2% maintenance). Vaginal lavage procedures
were performed as previously described [97, 99]. Briefly, vaginal cells were obtained by
flushing the vaginal canal with approximately 200 uL autoclaved water. The water containing
cells was placed on glass slides and air dried at room temperature. Smears were stained by
submerging the slides into a 0.1% crystal violet staining solution for 1 minute. The slides were
then submerged into ddH2O for 1 minute twice to remove extra stain. The slides were then air
dried prior to imaging. For long-term storage, glycerol can be added to the slides and covered by
cover slip. The slides were imaged using a Keyence microscope. The microscope was set to
Brightfield imaging condition with x20 PlanFluor lens.
Proestrus stage smears were identified by a high percentage of nucleated epithelial cells.
The epithelial cells are mostly oval in shape with nuclei that have a darker color in the stained
cells (Figure 2.1A). A small amount of keratinized epithelial cells may appear in proestrus
smears indicating the specific rat is in the process of transitioning to estrus stage (Figure 2.1B).
It is normal to see this phenomenon because the proestrus state is shorter than a day and the
smear collection is once a day in the morning. The estrus stage is characterized by unnucleated
keratinized epithelial cells. This stage is very easy to identify because the large keratinized

31

epithelial cells account for almost 100% of the cellularity (Figure 2.2A). Additionally, this stage
has a higher cellular density as compared to other stages. This can be identified even during the
collection before microscope observation. Sometimes cells can be rolled over becoming an
epithelial cell bar during this stage (Figure 2.2B). The metestrus stage comes right after the
estrus stage, and is characterized by all three cells types: nucleated epithelial cells, large
keratinized epithelial cells and small neutrophils. Small neutrophils are fragile and may be
broken during collection; they appear as smashed stains when observed under the microscope.
The cell density at this stage varies largely depending on the individual animals (Fig 2.3A, 2.3B).
Diestrus stage smears have similar cell composition to metestrus, but have relatively lower
cellularity compared to metestrus stages (Fig 2.4).

Figure 2.1: Representative vaginal smears for the proestrus cycle stage in female
Sprague-Dawley rats at 20 times magnification. A. Proestrus characterized by
nucleated epithelial cells. B. Proestrus characterized by nucleated epithelial cells with
some anucleated keratinized epithelial cells. (1) nucleated epithelial cells. (2)
anucleated keratinized epithelial cells.
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All the stages of vaginal lavage smears need to be compared within each rat. It is
important to note that the estrus cycle is a dynamic process. Evaluating multiple days of smears
is the best practice for deciding the stage of an individual female. Comparing the same stage
between different rats does not typically help with determining estrus stage.

Figure 2.2: Representative vaginal smears for the estrus cycle stages in female
Sprague-Dawley rats at 20 times magnification. A. Estrus characterized by large
anucleated keratinized epithelial cells. B. Estrus characterized by large nucleated
epithelial cells with some anucleated keratinized epithelial cells rolled over. (2)
anucleated keratinized epithelial cells; (2.1) epithelial cell bar.
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Figure 2.3: Representative vaginal smears for the metestrus cycle stages in female
Sprague-Dawley rats at 20 times magnification. A. Metestrus characterized by large
anucleated keratinized epithelial cells, nucleated epithelial cells and neutrophils. B.
Metestrus stage with higher cellularity. (1) nucleated epithelial cells. (2) anucleated
keratinized epithelial cells. (3) neutrophils.

Figure 2.4: Representative vaginal smears for the diestrus cycle stages in female
Sprague-Dawley rats at 20 times magnification. A. B. Diestrus characterized by
large anucleated keratinized epithelial cells, nucleated epithelial cells and
neutrophils. (1) nucleated epithelial cells. (2) anucleated keratinized epithelial
cells. (3) neutrophils.
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2.1.3 Hormone treatment. OVX with hormone replacement treatment samples were
kindly donated by Dr. Rahimian’s lab. Female Sprague-Dawley rats (Charles River) underwent
ovariectomy at 6 weeks of age, and hormone treatment or placebo was started at 6 weeks of age
(N = 6 per group). 17 beta-estradiol release pellets were implanted subcutaneously in the
hormone treatment group; 1 pellet per animal containing 1.5 mg of estradiol with a 60-day
release profile. All animals were sacrificed 45 ± 2 days after start of hormone or placebo
treatment.
Castrated male Sprague-Dawley rats were given testosterone or vehicle subcutaneously
(N = 6 per group) to evaluate the effects of hormone replacement. Males were castrated at 10
weeks of age, and testosterone or vehicle treatment was started at 12 weeks of age. Testosterone
(3 mg/kg sc) was dissolved in sesame oil and administered for 14 days. The same volume of
sesame oil was administered to the control (vehicle) group over the same time period.
All tissues were collected as described in section 2.1.1.
2.2. PCR Method Development and Validation
2.2.1 PCR primer validation. PCR primers used in all studies are detailed in Table 2.1
[1, 2]. Primers were validated prior to running qPCR. Primers were validated by running end
point PCR using an iTaq SYBRgreen kit (BioRad). The forward and reverse primers were
diluted to 250 nM for each reaction. After adding iTaq SYBRgreen super mix, forward and
reverse primer, 1ul of rat kidney cDNA was used to validate the primers. The thermocycler was
set following manufacturer’s instruction for the iTaq kit. The PCR product size was verified by
running 1% agarose gel separation (Figure 2.5).
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Table 2.1: Primer sequences and amplicon size.
Gene
MCT1
MCT4
SMCT1
CD147
r18S

F/R

Primer 5'-3'

F

GCTGTCATGTATGCCGGAG

R

CAATCATAGTCAGAGCTGGG

F

GCTGGCTATGCTGTATGGC

R

TTGAGAGCCAGACCCAAGC

F

GTTGCTGGTGGGGATTCTTA

R

CCACTGTGGTCTGGGAAGTT

F

GGCACCATCGTAACCTCTGT

R

CAGGCTCAGGAAGGAAGATG

F

GTTGGTTTTCGGAACTGAGGC

R

GTCGGCATCGTTTATGGTCG

Size (bp)
204
185
200
211
206

A

B

Figure 2.5: PCR product verification. A. Rat MCT1, MCT4, CD147 and 18s PCR
products verified on agarose gel imaged with ChemiDoc Touch Imaging System
(BioRad). B. Rat SMCT1 PCR product (in quadruplicate) verification imaged
with Benchtop 2UV Transilluminator (UVP) and Canon PowerShot camera.
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2.2.2 Plasmid generation for qPCR standards. Plasmid DNA containing a genespecific amplicon was needed to serve as standards for real time PCR. A TOPO TA Cloning kit
(Thermo Fisher Scientific) was used to clone the amplicon into E. coli. The desired PCR
product was inserted in to the pCR 2.1-TOPO TA plasmid vector (Figure2.6) and transformed
into E. coli TOP10 one-shot cells following the manufacturer’s instructions with no
modifications. pCR 2.1-TOPO TA vector was used in this kit which contains an ampicillin
resistance gene for selection. Taq polymerase added a single deoxyadenosine (A) to the 3’end of
the PCR product. The PCR product was inserted into the lacZ gene on the vector plasmid. E.
coli that express the lacZ gene have functional galactosidase which appears blue on media
containing X-gal. If the lacZ gene is inserted with the PCR product, the colony would appear
white on the culture LB-Amp/X-gal plates [100].
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Figure 2.6: pCR 2.1-TOPO TA vector. Plasmid vector contains Ampicillin and Kanamycin
resistance genes. PCR product is inserted to the lacZ gene (Invitrogen.
https://www.thermofisher.com/order/catalog/product/K203001?SID=srch-srp-K203001).
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Figure 2.7: Representative E. coli culture LB-Amp/X-gal plates.

Two different volumes of E. coli were plated on LB-Amp/X-gal plates in order to get
optimal colony distribution (100 ul of bacteria reaction/ 50 ul bacteria plus 50ul SOC medium
was used for generation of all plasmids). Bacteria were grown at 37oC overnight (Figure 2.7).
White colonies (containing plasmid) were selected and grown overnight at 37oC (with shaking at
200 rpm) in 5 ml LB media containing 100 μg/ml ampicillin. The E. coli culture was stored by
using 0.85 mL of culture with 0.15 mL of glycerol and was stored at -80°C. Only cultures that
were verified to contain the correct amplicon (as described in section 2.2.3) were retained for
future use. Plasmid DNA was isolated from opaque cultures using a PureLink Quick Plasmid
Miniprep Kit (Thermo Fisher Scientific) following the manufacturer’s protocol. TE buffer was
used to elute plasmid DNA and plasmid DNA concentration was determined using a Nanodrop
(Thermo Fisher Scientific).
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2.2.3 Plasmid DNA verification. After purification, the plasmid DNA was digested
using EcoR1 and run on a 1% agarose gel to confirm successful insertion of the amplicon. The
PCR amplicon used for cloning served as a positive control for the proper size of gene of interest
in the agarose gel analysis. All genes have been validated as shown in Figure 2.8 and Figure 2.9.

Figure 2.8: MCT1 Plasmid DNA verification. M1 representing MCT1 PCR
product as positive control. + EcoR1 treated, - not treated. Plasmids 1, 3 and 4
contained amplicons of the correct size. Figure imaged with Benchtop 2UV
Transilluminator (UVP) and Canon PowerShot camera.
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Figure 2.9: Plasmid DNA verification. A. MCT4 plasmid DNA verification.
Plasmid 1 contained an amplicon of the correct size and was used in further studies.
B. SMCT1 plasmid DNA verification. Both plasmids contained the correct size
amplicon. C. CD147 plasmid DNA verification. Plasmids 1, 2 and 3 contained the
correct size amplicon. D. 18s plasmid DNA verification. Plasmids 2, 3, and 4
contained the correct size amplicon. Gene-specific PCR amplicons were loaded in the
first lane of each gel as a positive control. + EcoR1 treated, - not treated.

Serial dilutions (10-3 to 10-7) of plasmid DNA for each gene of interest were used as
standards to confirm qPCR running conditions and efficiency. Quantitative analysis of
monocarboxylate transporter and ancillary protein mRNA expression was performed utilizing
iTaq Universal SYBR Green Supermix following the manufacturer’s instructions. A standard
curve was used for every block of samples run, functioning as standards for quantitative analysis
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and also as an indicator of qPCR efficiency (Figure 2.10). The PCR efficiency in each run
should be higher than 85% and should be consistent between runs for a given gene of interest.
All standards were run in duplicate. The house-keeping gene 18S and Alien RNA were utilized
for data normalization. The purity of all qPCR products was determined by melt curve (Figure
2.11.)
Following all the steps mentioned above, the primers were all validated, and PCR
conditions were optimized. The plasmid DNA was created, and standards demonstrated
reproducibility and suitability for qPCR analysis of mRNA expression.
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Figure 2.10: Standard curves for each gene of interest. A. MCT1 standard curve. B.
MCT4 standard curve. C. SMCT1 standard curve. D. CD147 standard curve. E. 18s
standard curve. All standard curves demonstrate good replication efficiency and
repeatability.
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Figure 2.11: PCR melt curves. Each amplicon has a unique melt curve, and consistency in
melt curve is an indicator that a single product is formed during the PCR reaction. A.
MCT1 melt peak. B. MCT4 melt peak. C. SMCT1 melt peak. D. CD147 melt peak. E.
18s melt peak.
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2.2.4 Sample preparation. RNA was isolated using a PureLink RNA Mini Kit
(PureLink RNA Mini Kit) from frozen tissue (around 30 mg) following the manufacturer’s
instructions. In brief, the frozen tissue was homogenized in the lysis buffer containing 1% 2mercaptoethanol. After centrifugation, the supernatant was added to an equal volume of 70%
ethanol and added to the cartridge to bind RNA/DNA. DNase I was incubated on the cartridge
for 15 minutes at room temperature to remove DNA from the sample. After going through
DNase incubation, wash buffer I and wash buffer II was used to wash the cartridge. RNA was
recovered from the cartridge using 30 - 80 μL of molecular grade water depending on the size of
used tissue.
RNA concentration was determined by Nanodrop (Thermo Fisher Scientific). RNA
integrity is important for the accuracy of downstream qPCR analysis of mRNA expression;
however, mRNA is very sensitive to RNase enzymes, which are ubiquitously present in all
tissues and can lead to RNA degradation. FlashGel RNA cassettes (Lonza) were used to verify
the integrity of all RNA samples prior to qPCR analysis. RNA integrity is demonstrated by the
presence of two clear bands representing 28S and 18S rRNA with an intensity ratio of 2:1 [101].
Representative results of RNA integrity evaluations are shown in Figure 2.12. No clear bands on
the FlashGel indicated that the isolated mRNA was degraded and not suitable for downstream
analysis (Figure 2.12A). Two clear bands represent good quality mRNA samples which can be
used for subsequent mRNA analysis (Figure 2.12B)
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Figure 2.12: RNA integrity evaluation on RNA Flash Gels. Two distinct bands
represent 28S and 18S rRNA indicate intact RNA samples. A. Example of degraded
kidney mRNA samples from female rats. There are no visible 28S and 18S bands. B.
Representative liver mRNA samples from female rats demonstrating intact RNA
samples.

In order to perform qPCR to evaluate transcription of transporter genes and ancillary
proteins, cDNA was synthesized from mRNA. The concentration of mRNA was determined
using Nanodrop (Thermo Fisher Scientific). 2000 ng of total RNA was added to the cDNA
synthesis reaction. 5x iScript (BioRad) provided the mix including the reaction buffer, dNTPs
and salt buffer. To each 40 μL reaction mixture, 2 μL of 60,000 times diluted Alien RNA was
used as an external standard. The reaction was placed in the thermocycler and heating protocol
was as follows: 25 °C for 5 minutes, 42 °C for 30 min and 85 °C for 5 minutes. The cDNA at
4 °C for immediate use and store at -20 °C for future use.
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2.2.5 qPCR. To perform qPCR, a master mix was made as follows: for each reaction, 10
μL of iTaq Universal SYBR Green Supermix (BioRad), 7 μL of molecular grade water, 1 μL of
100 μM forward primers, and 1 μL of 100 μM reverse primers. 19 μL of master mix was added
to each PCR reaction tube and 1 uL of cDNA was added to the side of the tube. All tubes were
centrifuged immediately prior to placement in the thermal cycler to prevent early undesirable
reactions with the master mix. iTaq SYBR Green Supermix (BioRad) include double-stranded
DNA binding dye SYBR Green, which emits fluorescence as an indicator for the amount of
DNA. The emitted fluorescence was measured at the end of each thermal cycle (40 cycles per
PCR reaction) and copy number of the gene of interest can be calculated accordingly utilizing a
standard curve [102, 103].
There are three major steps in the PCR reaction: denature, annealing and elongation.
Based on previous primer validation and method development, the optimal two-step thermal
cycle protocol for all the genes in this dissertation are shown in Figure 2.13. 95°C is the
polymerase hot start and DNA denaturation temperature. Annealing and elongation are
combined in this two-step method and are set at 60°C for optimal primer binding and elongation.
Melting temperature was accessed from 65°C to 95 °C for each plate of qPCR analysis.
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Figure 2.13: Thermocycler temperature settings for qPCR analysis.

2.3 Analysis of Protein Expression
2.3.1 Total cellular protein and membrane protein preparation.
2.3.1.1 Preparation of liver and kidney samples. Rat liver and kidney tissue (20 – 30 mg)
was homogenized in 600 μL ice-cold radio-immunoprecipitation assay buffer (RIPA) containing
Protease Inhibitor Cocktail (UltraCruz, Santa Cruz Biotechnology) and rotated for 15 minutes at
4 ℃. The sample was then centrifuged at 14,000 x g for 15 minutes at 4°C to remove cell debris.
The supernatant was retained for analysis of whole cell protein expression and stored at -20 °C
until analysis. Protein concentration was measured using the BCA assay (Pierce BCA Protein
Assay Kit, Thermo Fisher Scientific)
Membrane bound protein was extracted from liver and kidney using a ProteoExtract
Native Membrane Extraction kit (EMD Millipore) following the manufacturer’s instructions. In
brief, tissue (around 40 mg) was homogenized in the provided lysis buffer with protease
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inhibitor. The sample was rotated at 4 ℃ for 10 minutes on a rotatory shaker. The sample was
then centrifuged at 16,000 x g and 4°C for 15 minutes. The supernatant (soluble fraction) was
kept for method validation. The pellet was homogenized in lysis buffer II and rotated at 4 ℃ for
30 minutes. After centrifugation at 16,000 x g and 4°C for 15 minutes, the supernatant
containing membrane bound proteins was retained. The membrane and soluble fractions were
stored at -20oC, and Na+/K+ ATPase expression was evaluated by western blot to verify
membrane isolation. Na+/K+ ATPase enrichment in the membrane fraction of the sample
indicated successful membrane extraction. Liver and kidney membrane extraction is illustrated
by Na+/K+ ATPase enrichment western blot (Figure 2.14)
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Figure 2.14: Representative liver and kidney membrane protein extraction verification.
Membrane protein and soluble fraction of the tissue samples from different tissue. (A
and B) Liver. (C and D) Kidney.
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2.3.1.2 Preparation of intestinal samples. For intestinal samples, the same membrane
extraction kit and protocol described above was used. However, western blotting results for
Na+/K+ ATPase enrichment did not demonstrate sufficient membrane extraction for all intestinal
regions. As seen in Figure 2.15A, ileum samples demonstrated acceptable membrane enrichment
with the soluble fraction having undetectable protein expression; however, duodenum and jejunum
membrane isolation was not sufficient (Figures 2.15B and 2.15C). The extraction process was
repeated on the duodenum and jejunum samples, and membrane isolation did not show

Figure 2.15: Membrane protein extraction verification. Membrane protein and soluble
fraction of the tissue samples from the three intestinal segments: A. Ileum. B.
Duodenum. C. Jejunum.
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improvement in these two segments, so optimization of membrane enrichment in the intestine was
required. For consistency between segments, the protocol was optimized in all regions.
In the previous sample preparation, whole intestinal segments were homogenized for
protein analysis. To improve enrichment, the tissue samples were processed differently with the
isolation of enterocytes occurring prior to homogenization. Ice-cold saline containing protease
inhibitor cocktail (Santa Cruz Biotechnology) was used when isolating enterocytes. Briefly,
after cutting a piece of intestinal segment, the small piece of tissue was submerged in the abovementioned saline. The intestinal tubule was cut open and flushed with ice-cold saline
immediately to inhibit residual protein enzymes and bacteria. The mucosal layer was then
collected and homogenized in lysis buffer containing protease inhibitors. The sequential
membrane protein extraction was conducted as previously described following the
manufacturer’s instructions. Na+/K+ ATPase enrichment western blot validation was performed
(Figure 2.16).

The new methodology of sample preparation showed improvement of membrane

isolation outcome. The membrane Na+/K+ ATPase enrichment western blot demonstrated that
duodenum membrane protein was extracted successfully (Figure 2.16A). Ileum membrane
protein extraction was sufficient as well with the updated method (Figure 2.16B).
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Figure 2.16: New membrane protein extraction verification. Membrane protein and
soluble fraction of the tissue samples from the two intestinal segments: (A)
Duodenum. (B). Ileum.

2.3.2 Western blotting. Protein concentrations were determined using a Pierce BCA
Protein Assay Kit (ThermoFisher) with bovine serum albumin as the standard. Total whole cell
protein (15 μg) or membrane fraction (5 μg) were mixed with 2x or 4x Laemmli sample buffer
(BioRad) and heated at 37°C for 30 minutes. Samples were separated at 200V on 10% TGX Fast
Cast gel (BioRad) and transferred to nitrocellulose membranes at 100V for 25 minutes.
Membranes were incubated in SEA Blocking buffer (Thermo Fisher Scientific) or 5% milk in
PBST for 1 hour at room temperature. Membranes were incubated with primary antibody on a
shaker overnight at 4°C. Primary antibodies were rabbit anti-MCT1 (AB3540P, Millipore) at
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1:1350 dilution, anti-MCT4 (AB3314P, Millipore) at 1:1000 dilution, goat anti-CD147 (SC-9757,
Santa Cruz) at 1:1000 dilution, rabbit anti-SMCT1 (ARP44110_P050, AVIVA) at 1:1000 dilution,
rabbit anti- Na+/K+ ATPase (sc-28800, Santa Cruz) at 1:1000 dilution. The membranes were
washed 3 times for 10 minutes in PBST and then incubated with secondary antibody for 1 hour at
room temperature. Secondary antibodies were anti-goat or anti-rabbit IgG (Abcam) at 1:10,000
dilution, anti-rabbit (Santa Cruz) at 1:5000 dilution, anti-goat (Abcam) at 1:10,000 dilution. The
membranes were then washed 3 times for 10 minutes with PBST and then incubated with Clarity
ECL reagent (BioRad) for 2 minutes. Protein bands were visualized using a Chemidoc Touch
Imaging System (BioRad). Band density was determined using BioRad Image lab software with
Na+/K+ ATPase as a loading control.
In order to demonstrate the western blot system is a reliable method for protein
quantification, two different amounts of membrane protein were loaded to a western blot gel and
the MCT1 antibody was used to demonstrate the quantification method. The ratio of the MCT1
band intensity at 2.5 and 5 μg is 0.5099 ± 0.05258 (Figure 2.17). This ratio demonstrated that
protein band intensity tested via western blot is quantifiable.

Figure 2.17: Western blot validation. Different amount of protein was loaded on western blot
and MCT1 protein was tested.
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Figure 2.18: Western blot of Na+/K+ ATPase as loading control. A. Representative
Na+/K+ ATPase for duodenum samples. B. Representative Na+/K+ ATPase for ileum
samples. 5μg of membrane protein was loaded to each well.

For intestinal samples, Na+/K+ ATPase membrane expression exhibited variability
between samples when 5 μg of membrane protein was loaded for each sample as seen in Figure
2.18, some of the samples had markedly higher band density while some of the others had
relatively low signal. The total amount of protein loaded on the gel can be an alternative
loading control, so it was evaluated as an alternative to using a house-keeping gene. Stain-free
gels (TGX Stain-Free™ FastCast™ Acrylamide 10%, BioRad) was used for total protein
quantification for intestinal samples. On the stain free gels, fluorophores were covalently
bonded to the proteins. With a short activation, the emitted UV light can be detected from the
gel or the nitrocellulose membrane (Figure 2.19). Four forms of data can be obtained from stain
free gel/blot imaging: total band volume, adjusted total band volume, total lane volume and
adjusted total lane volume. In order to evaluate which data form best describes the amount of
protein, a calibration curve was created by loading a series of protein amounts. According to
Figure 2.20 and Figure 2.21, the total lane volume had the best linearity on both the gel (R2
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=0.993) and the blot (R2 =0.993). The gel was imaged right after electrophoresis and the
nitrocellulose membrane was imaged after immediately following transfer. Blot analysis was
chosen due to consistent background and ease of operation compared to gel imaging.

Figure 2.19: Ileum total protein imaging. A. Stain Free gel imaging with 45 seconds
activation. B. Nitrocellulose membrane imaging after transfer. Images were obtained
by ChemiDoc Touch Imaging system.
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Figure 2.20: Ileum protein calibration curve on Stain Free gel. Total band volume,
adjusted band volume, total lane volume and adjusted total lane volume was obtained
by BioRad ChemiDoc Touch imaging system.
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Figure 2.21: Ileum protein calibration curve on nitrocellulose membrane. Total band
volume, adjusted band volume, total lane volume and adjusted total lane volume was
obtained by BioRad ChemiDoc Touch imaging system.
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SMCT1 (SLC5A8) antibody (ARP44110_P050, AVIVA) was a polyclonal antibody and
had a lot of non-specific binding (Figure 2.21A). For other polyclonal antibodies, there was only
one band at the correct protein size; however, there were two bands that were very close to each
other at around size 60 kD for SMCT1 antibody. To identify which band was the SMCT1 band
an SMCT1 blocking peptide (AAP44110, AVIVA) was combined with the SMCT1 primary
antibody to identify the correct band. 1ul/mL of the blocking peptide was added to the primary
antibody, and western blot membranes were incubated overnight at 4 oC. All other western blot
processes were conducted as described above for SMCT1.
A blocking peptide is a peptide that has an amino acid sequence that contains the specific
target protein epitope. The peptides will compete with the sample proteins and block the
antibody in the reaction. When sufficient blocking peptide is added to the antibody dilution,
there will be no binding to the target sample protein and no band will be observed on the
nitrocellulose membrane. As seen in Figure 2.22B, there was only one band around 60 kD when
incubating the primary antibody with the blocking peptide. The actual SMCT1 protein band
disappeared compared to Figure 2.22A. In this case, we concluded that the lower band around
60kD is the SMCT1 protein band, and the top band is the nonspecific binding band, therefore,
the bottom band will be used for densiometric analysis of SMCT1 protein expression in the
intestine and kidney.
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Figure 2.22: SMCT1 band identification utilizing an antibody specific blocking peptide. (A)
SMCT1 western blot with primary antibody alone. (B) SMCT1 western blot incubated with
primary antibody and SMCT1 peptide together.

2.4 Materials
LB/Amp plates: 20 g of LB-Agar powder dissolved in 500 mL ddH2O. Autoclave for 15
minutes. Allow to cool to approximately 60oC and add ampicillin 500 μL, IPTG 500 μL, 1 ml xGal in to the solution. Pour 23 mL onto each plate, making sure there are no bubbles. Cool the
gel for 30 minutes at room temperature until solid. Store plates in the fridge at 4oC upside down
to prevent condensation.
Agarose gel (2%): 2 g agarose powder dissolved in 100 mL TBE buffer. Microwave the
mixture until liquid is clear. Cool the mixture in water bath until luke warm. 10 μL of SYBR
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safe DNA Gel Stain (Invitrogen) was added to the mixture. Pour the liquid into leveled gel
cassette, making sure there are no bubbles. Insert the comb and let the gel sit for 30 minutes.
Remove the comb before use. Pour TE buffer to a level that is enough to cover agarose gel.
Acrylamide gel: 0.75 mm glass plate were used for gel casting. TGX™ FastCast™
Acrylamide Kit, 10% (Bio-Rad) or TGX™ Stain Free FastCast™ Acrylamide Kit, 10% was used
for all gels. For every two gels, Resolver A 4 ml and Resolver B 4 ml were mixed with 40 uL of
10% APS and 4 uL TEMED. 2 ml Stacker A, 2 ml Stacker B, 20 uL10% APS, and 4 uL of
TEMED were mixed gently. The resolver was loaded to the gel first and then stacker was
loaded. The 10 well or 15 well comb was inserted and the gel polymerized for 30 minutes at
room temperature.
RIPA buffer: 4.38 g NaCl (150 mM), 5 ml Triton X (1%), 25 ml 10% sodium
deoxycholate (0.5%), 5 ml 10% SDS (0.1%), 3.03 g Tris Base. Mix above mentioned
ingredients and adjust to pH 8.0. QS with ddH2O to 500 ml. RIPA buffer can be stored at 4°C.
A protease inhibitor tablet (Santa Cruz Biotechnology) was added to every 50 ml RIPA buffer.
RIPA containing protease inhibitor was stored at -20 °C.
Blocking buffer (5% non-fat milk): Weigh 2.5 g milk, add ddH2Oto 50 ml.
10x Running buffer: 60.4 g TrisBase, 288 g Glycine, 20 g SDS. Mix above mentioned
ingredients and qs with ddH2Oto 1L.
10x Transfer buffer: 30. 2 g TrisBase, 144 g Glycine. Mix above mentioned ingredients
and qs with ddH2O to 1 L. Transfer buffer (1X): 100 ml 10x transfer buffer, 700 ml ddH2O, 200
ml methanol.
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10x PBS: 80 g NaCl, 2 g KCl, 11.5 g Na2HPO4.7H20, 2 g KH2PO4. Mix above
mentioned ingredients and qs with ddH2O to 1L. PBST: 10x PBS 100 ml, 1 ml Tween, qs with
ddH2O to 1 L.
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Chapter 3: Sex Hormones Regulate Rat Hepatic Monocarboxylate Transporter Expression
and Membrane Trafficking

This chapter has been published in J Pharm Pharm Sci, 20(1): 435-444, 2017.
Authors: Jieyun Cao, Michael Ng and Melanie Felmlee

3.1 Introduction
The liver is the major metabolic organ in the body with metabolism governed by drug
metabolizing enzymes and transporter expression in hepatocytes. The solute carrier superfamily
of transporters (SLC) are located on the basolateral membrane of hepatocytes and function to
move drug substrates into and out of the cells with transport kinetics determined by substrate
affinity and membrane transporter expression. These transporters may be a limiting factor in
intracellular drug accumulation in hepatocytes, thereby determining the rate and extent of drug
metabolism. Interindividual variations in transporter expression in the liver may contribute to
differences in drug metabolism and systemic drug concentrations, leading to reduced efficacy or
toxicity.
Monocarboxylate transporters (MCTs) are involved in the active transport of endogenous
monocarboxylates such as ketone bodies, lactate and pyruvate, as well as drugs such as gammahydroxybutyrate, salicylic acid, nicotinate, nateglinide and valproic acid [9, 88]. Proton-coupled
monocarboxylate transporters are encoded by the SLC16A gene family. There are 14 members
in the SLC16A gene family discovered by sequence homology [9]. Currently, there are 5
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members of the family (MCT1-4, MCT7) demonstrated to be proton-dependent MCTs. Among
those, MCT1 (SLC16A1), MCT2 (SLC16A7), and MCT4 (SLC16A3) are expressed in the liver
of humans and rodents [9, 104]. Recently, there is evidence that MCT7 (SLC16A6) facilitates
the efflux of ketone bodies out of hepatocytes during fasting in a zebrafish model [11].
Transport of substrates by MCTs can be bi-directional and is coupled with proton transport, and
is driven by proton gradients instead of ATP [105]. Ancillary proteins are involved in MCT
membrane trafficking and functionality on the plasma membrane. CD147 (basigin) functions as
an ancillary protein for MCT1, MCT3 (SLC16A8) and MCT4. Formation of MCT/CD147
heterodimers in the endoplasmic reticulum is important for efficient trafficking of the
transporters to the plasma membrane [17, 24].
Previous studies have shown that MCT expression can be regulated by sex hormones.
Enoki et al. (2006) reported that testosterone increased skeletal muscle MCT1 and MCT4 whole
cell protein expression. However, MCT1 expression in the heart was not increased, suggesting
MCTs are regulated in a tissue-specific manner [50]. Additionally, rat Sertoli cells treated with
17beta-oestradiol or dihydrotestosterone had decreased MCT4 mRNA levels [51].
Hypophysectomized rats, with reduced endogenous testosterone levels, showed increased
testicular MCT2 mRNA expression that was reversed with testosterone treatment ex vivo [52].
Inhibition of estrogen related receptor alpha decreased MCT1 expression in MC4-L2 human
breast cancer -bearing BALB/c mice indicating that estrogen may be involved in MCT1
regulation [38] These data suggest that MCTs are regulated by sex hormones in a tissue-specific
manner; however, there is a lack of information in the literature evaluating the role of sex
hormones on MCT expression in tissues involved in drug disposition.
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The objective of this study was to quantitatively evaluate hepatic MCT1, MCT4 and
CD147 mRNA, and total cellular and membrane protein expression in males, over the estrus
cycle in female rats and in the absence of female sex hormones. We utilized five groups of
female rats (proestrus, estrus, metestrus, and diestrus stages) and ovariectomized rats to evaluate
MCTs and ancillary protein expression in rat liver over the estrus cycle as a response to the
fluctuation in female sex hormones levels.
3.2 Methods
3.2.1 Animals, estrus staging and tissue collection. Male and female Sprague Dawley
(SD) rats and ovariectomized females were obtained from Envigo at 8 weeks of age, and were
housed in a temperature controlled room with a 12-hour day/night lighting cycle. All rats were
fed standard rat chow and water ad libitum. Estrus stages of female rats were monitored daily by
vaginal lavage smear for 8 – 11 days (at least two estrus cycle) between 10 am and 12 pm.
Smears were stained with crystal violet [99] and imaged using a Keyence microscope. Vaginal
lavage procedures were performed as previously described [97] Vaginal lavage was performed
immediately before sacrificing to confirm their estrus stage, and each estrus stage evaluated
represents an independent group of animals. Liver samples were collected (3 – 5 per group; total
of 24 animals) from all animals at 10 weeks of age following exsanguination under isoflurane
anesthesia between 10 am to 12 pm. Age-matched ovariectomized female samples were
collected two weeks post-surgery. Liver samples were immediately snap frozen in liquid
nitrogen and stored at -80oC until analysis. All experiments were approved by the Institutional
Animal Care and Use Committee at the University of the Pacific.
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3.2.2 qPCR. Liver (~10 mg) was homogenized in lysis buffer and RNA was isolated
using PureLink RNA Mini kit (Invitrogen) according to manufacturer’s instructions. RNA
concentration and purity was determined by Nanodrop (Thermofisher). RNA integrity was
verified by RNA Flash Gels (Lonza) to visualize 18S and 28S rRNA. 2000 ng of total RNA was
added to each 40 μl cDNA synthesis reaction, which was reverse transcribed to cDNA using
iScript Reverse Transcription Supermix (BioRad). Primer sequences, annealing temperatures
and product sizes for quantitative real-time PCR are shown in Table 1 [1, 2]. Primers were
validated by running endpoint PCR with 250 nM forward and reverse primers, 1 μl of cDNA and
iTaq Universal SYBR Green Supermix (BioRad) following the manufacturer’s instructions.
PCR product size was confirmed by running the amplicons on a 1% agarose gel (Figure 1). A
TOPO TA Cloning kit (Invitrogen) was used to clone the amplicon into E. coli and produce
plasmid DNA containing the target sequence. The plasmid DNA was then digested using EcoR1
and run on a 1% agarose gel to confirm successful insertion of the amplicon. Serial dilutions
(10-3 to 10-7) were used as standards to confirm qPCR running conditions and efficiency.
Quantitative analysis of MCT1, MCT4, and CD147 was performed with iTaq Universal SYBR
Green Supermix as described above on CFX96 Connect (BioRad) with a standard curve run on
every plate. The house-keeping gene 18S was evaluated for data normalization. The purity of
all qPCR products was determined by melting curve. Data was quantified (in arbitrary units)
based on the gene-specific standard curve.
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Table 3.1: Primer sequences, amplicon sizes, and annealing temperatures for qPCR assays [1, 2].
Size
Gene

F/R

Primer 5'-3'

F

GCTGTCATGTATGCCGGAG

R

CAATCATAGTCAGAGCTGGG

F

GGCACCATCGTAACCTCTGT

R

CAGGCTCAGGAAGGAAGATG

F

GCTGGCTATGCAGTATGGC

R

TTGAGAGCCAGACCCAAGC

F

GTTGGTTTTCGGAACTGAGGC

R

GTCGGCATCGTTTATGGTCG

MCT1

CD147

MCT4

18s

(bp)

Annealing
temperature

204

60℃

211

60℃

185

60℃

206

60℃

Figure 3.1: Primer validation for real time PCR.

3.2.3 Western blotting. Liver tissue was homogenized in 600 μl ice-cold
radioimmunoprecipitation assay buffer (RIPA) containing Protease Inhibitor Cocktail
(UltraCruz, Santa Cruz Biotechnology) and rotated for 15 minutes at 4℃. The sample was
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centrifuged at 14000 x g for 15 minutes at 4°C to remove cell debris. The supernatant was
retained for analysis of whole cell protein expression and stored at -20 °C until analysis.
Membrane bound protein was extracted from liver using a ProteoExtract Native Membrane
Extraction kit (Millipore) following the manufacturer’s instructions. The membrane and soluble
fractions were retained, and stored at -20oC, and Na+/K+ ATPase expression was evaluated by
western blot to verify membrane isolation. Protein concentrations were determined using a
Pierce BCA Protein Assay Kit (ThermoFisher) with bovine serum albumin as the standard.
Total whole cell protein (15 μg) or membrane fraction (5 μg) were mixed with 2x Laemmli
sample buffer (BioRad) and heated at 37°C for 30 minutes. Samples were separated at 200V on
10% TGX Fast Cast gel (BioRad) and transferred to nitrocellulose membranes at 100V for 25
minutes. Membranes were incubated in SEA Blocking buffer (ThermoFisher) for 1 hour at room
temperature. Membranes were incubated with primary antibody overnight at 4°C. Primary
antibodies were rabbit anti-MCT1 (AB3540P, Millipore) at 1:1350 dilution, anti-MCT4
(AB3314P, Millipore) at 1:1000 dilution goat anti-CD147 (SC-9757, Santa Cruz) at 1:1000
dilution, rabbit anti- Na+/K+ ATPase (sc-28800, Santa Cruz) at 1:1000 dilution. Secondary
antibodies were anti-goat or anti-rabbit IgG (Abcam) at 1:10,000 dilution, anti-rabbit (Santa
Cruz) at 1:5000 dilution. The membranes were washed 3 times for 10 min in PBST and then
incubated with secondary antibody for 1 hour at room temperature. The membranes were then
washed 10 min for 3 times and incubated with Clarity ECL reagent (BioRad) for 2 min. Protein
expression was visualized using a Chemidoc Touch System (BioRad). Band density was
determined using BioRad Image lab software with Na+/K+ ATPase as a loading control.
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3.2.4 Data analysis. Data are expressed as mean ± standard deviation. Data was
analyzed in GraphPad Prism 6 using a Kruskal-Wallis nonparametric one-way analysis of
variance (ANOVA) with a Dunn’s post hoc test. It was considered statistically significant when
the p value was less than 0.05. Correlation analysis in GraphPad Prism 6 was used to evaluate
the relationships between mRNA expression and whole protein expression, and whole protein
expression and membrane expression for all genes evaluated, and between CD147, MCT1, and
MCT4 membrane expression.
3.3 Results
3.3.1 Estrus cycle staging. After imaging, female estrus stages were identified by cell
types in the smear [97]. Vaginal lavage smears were evaluated daily to predict each rats’ estrus
stage on the day of tissue collection. The last vaginal lavage smear was acquired immediately
prior to tissue harvesting and was used to confirm the estrus stage prediction. Representative
imaging of the four stages are shown in Figure 2.
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Figure 3.2: Representative vaginal smears for the four estrous cycle stages in female
Sprague-Dawley rats at 20 times magnification. A. Proestrus characterized by large
nucleated epithelial cells (1). B. Estrus characterized by large anucleated keratinized
epithelial cells (2). C. Metestrus characterized by a combination of epithelial cells and
neutrophils (3). D. Diestrus characterized by low cellularity, and a combination of
neutrophils, small and large epithelial cells.

3.3.2 MCT1 expression. MCT1 mRNA expression varied significantly based between
groups (P = 0.0199), with lower mRNA expression in the presence of female sex hormones, as
compared to males and ovariectomized females (Figure 3A). Female rats in the metestrus stage
demonstrated statistically significant decreases in mRNA expression (~90%) compared to OVX
rats. mRNA expression trended higher in OVX females as compared to males. Whole cell
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MCT1 expression varied based on sex (P = 0.0632) and trended lower in all estrus stages, with
ovariectomized females and males having the highest protein expression with greater variability
than was observed for mRNA expression (Figure 3B). In contrast, membrane expression of
MCT1 was highest in ovariectomized rats (approximately 50% higher than males) and differed
based on female estrus cycle stages (Figure 3C), similar to the pattern observed in mRNA
expression. MCT1 membrane expression varied significantly with sex (P = 0.0086) with males
and OVX females having higher MCT1 membrane expression than all female estrus cycle stages.
In proestrus females, membrane MCT1 expression was significantly lower compared to
ovariectomized females (~75%). Females in the estrus stage had higher expression than the
other stages, but expression was still lower than OVX (55%).
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Figure 3.3: MCT1 mRNA, whole cell and membrane bound protein expression. A. Foldchange in MCT1 mRNA in Sprague Dawley rat liver. Data are presented as mean ± SD. B.
Whole cell MCT1 protein expression in liver. Data normalized to Na+/K+ ATPase
expression, and presented as mean ± SD. C. MCT1 membrane protein expression. Data
normalized to Na+/K+ ATPase expression, and presented as mean ± SD. *p < 0.05
compared to male group. #p < 0.05 compared to OVX group. (n = 3 - 5 rats)
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3.3.3 MCT4 expression. MCT4 mRNA varied significantly between groups (P =
0.0088; Kruskal-Wallis test) with all female estrous stages having lower expression as compared
to males and OVX females (Figure 4A). MCT4 mRNA level was lower compared to MCT1
with Ct values greater than 30 for MCT4. Whole cell MCT4 protein expression did not show
significant difference between sexes or among female estrus cycle stages (P = 0.6304), but this
may have been due to the large degree of variability in expression. Membrane expression of
MCT4 varied significantly with sex and estrus stage (P = 0.0186; Kruskal-Wallis test).
Membrane MCT4 expression was lower in females compared to males (50 – 75% lower) with
statistically significant decreased expression observed in the proestrus stage. OVX females had
lower membrane MCT4 when compared to males (approximately 60% lower).
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Figure 3.4: MCT4 mRNA, whole cell and membrane bound protein expression. A. Foldchange in MCT4 mRNA in Sprague Dawley rat liver. Data are presented as mean ± SD. B.
Total MCT4 protein expression in liver. Data normalized to Na+/K+ ATPase expression,
and presented as mean ± SD. C. MCT4 membrane protein expression. Data normalized to
Na+/K+ ATPase expression, and presented as mean ± SD. *p<0.05 compared to male group.
#
p<0.05 compared to OVX group. (n =3-5 rats)
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3.3.4 CD147 expression. Expression of CD147, the ancillary protein for MCT1 and
MCT4, is presented in Figure 5. There was no difference in mRNA expression of CD147 in the
liver over the estrus cycle, or between males and ovariectomized females (P = 0.2443).
Similarly, whole cell protein expression did not show any difference between sexes or
ovariectomized females (P = 0.8724). CD147 membrane expression was not statistically
different between sexes (P = 0.0749) but trended towards lower expression in all females.
Membrane protein expression of CD147 was lower in all females when compared to males (60 –
65% lower), with expression in ovariectomized females similar to all estrus stages suggesting
that androgens may be involved in membrane expression of CD147.
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Figure 3.5: CD147 mRNA, whole cell and membrane bound protein expression. A. Foldchange in CD147 mRNA in Sprague Dawley rat liver. Data presented as mean ± SD. B.
Whole cell CD147 protein expression in liver. Data normalized to Na+/K+ ATPase
expression, and presented as mean ± SD. C. CD147 membrane protein expression. Data
normalized to Na+/K+ ATPase expression, and presented as mean ± SD. *p<0.05
compared to male group. (n = 3 - 5 rats)
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3.3.5 Correlation analysis. To examine the correlation between mRNA and whole
protein expression, linear regression was performed on whole cell protein and mRNA expression
data. MCT1, MCT4 and CD147 whole protein expression was not correlated with their mRNA
expression indicating post-transcriptional regulation of expression (data not shown).
To evaluate if membrane expression correlated with whole protein expression, linear
regression was used to analyze membrane and whole protein expression data. In Figure 6A,
MCT1 membrane expression is positively correlated with MCT1 protein expression (R2 = 0.36, p
< 0.05), suggesting that membrane MCT1 expression is partially correlated with whole protein
expression. MCT4 membrane expression was not correlated with MCT4 whole cell expression
(Figure 6C), which indicates that MCT4 membrane expression is dependent on post-translational
regulation mechanisms. In addition, CD147 membrane expression does not correlate with
CD147 whole protein expression (data not shown).
In order to further examine if CD147 is responsible for MCT1 and MCT4 membrane
expression in the liver, correlations between membrane CD147 expression and membrane MCT1
and MCT4 expression were evaluated. MCT1 membrane protein expression showed a trend
towards correlation with CD147 membrane protein (Figure 6B); however, the relationship was
not statistically significant (R2 = 0.09, p > 0.05) likely due to the presence of two outlying
samples with very high MCT1 membrane expression. Both of these outliers were from OVX
females, and with the OVX group removed there was a significant correlation between MCT1
and CD147 membrane expression (R2 = 0.6789, p < 0.0001). This suggests that CD147 may not
be solely responsible for MCT1 localization to the plasma membrane, and MCT1 membrane
expression is exacerbated in the absence of female sex hormones. In Figure 6D, MCT4
membrane expression is significantly positively correlated with CD147 membrane expression
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(R2 = 0.40, p < 0.05). This indicates that CD147 is partially responsible for MCT4 membrane
localization, and that other ancillary proteins may contribute to trafficking MCT4 to the plasma
membrane.

Figure 3.6. A. Correlation analysis between MCT1 membrane and whole cell protein
expression. B. Correlation between CD147 membrane expression and MCT1
membrane expression. C. Correlation between MCT4 membrane protein and whole
cell protein expression. D. Correlation between CD147 membrane expression and
MCT4 membrane protein. (n = 24 rats)
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3.4 Discussion
Monocarboxylate transporters are involved in the distribution of nutrients and
pharmaceutical agents in the liver. Transport capacity is governed by MCT membrane
expression, and alterations in expression levels may lead to changes in systemic concentrations
and hepatic metabolism. Previous studies have reported that MCTs are regulated by sex
hormones in skeletal muscle and Sertoli cells [50, 51]; however, there is a lack of information in
tissues involved in drug disposition. The current study is the first analysis of sex hormonedependent regulation of MCTs with respect to mRNA and protein expression, and membrane
trafficking over the estrous cycle in female rats and in the absence of female sex hormones. We
have demonstrated that female sex hormones are involved in the hepatic regulation of MCT1
mRNA and protein expression. In contrast, MCT4 and CD147 demonstrated consistent
expression in the presence and absence of female sex hormones; however, males had higher
membrane expression of MCT4 and CD147.
The estrous cycle in rats is typically 4 to 6 days long with female sex hormones
fluctuating throughout the cycle. Diestrus can be between one and three days, with the other
stages 24 hours or less in duration [97]. In the present study, we evaluated the estrous cycle and
collected liver samples during a defined time window to better capture all of the stages of the
estrous cycle. Estradiol levels peak during the early portion of the proestrus stage, which often
occurs in the morning, and then return to baseline within 24 hours [106]. Luteinizing hormone,
follicular stimulating hormone and progesterone levels peak later during proestrus and decrease
to baseline at end of the proestrus day [106, 107]. During estrus, estradiol levels increase to a
lesser extent than during proestrus, and return to baseline during estrus [106]. Baseline estradiol
levels are observed in metestrus and diestrus stages [106]. Progesterone levels are elevated again
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during the diestrus stage [107]. Understanding the cycle-dependent changes in female sex
hormonal levels will aid in identifying the individual hormones that may be involved in the
regulation of MCTs and CD147.
Previous studies in rats have demonstrated sex hormone-dependent regulation of MCT1
mRNA and protein expression in a range of muscle types, focused on the role of testosterone.
Testosterone treatment increased MCT1 mRNA and protein expression in muscle; however, the
increases were muscle type dependent [50]. Consistent with the observations in rats, sex
differences in plasma lactate levels have been demonstrated following exercise in humans with
women having lower plasma lactate levels than men suggesting there is increased MCT1
expression in men [48]. We observed increased hepatic MCT1 mRNA and membrane
expression in males and OVX females consistent with the testosterone-mediated increases
demonstrated in rat muscle. Our results also suggest that female sex hormones may
downregulate MCT1 mRNA expression and reduce membrane trafficking, supported by the
estrous-cycle dependent fluctuations in MCT1 membrane expression. In contrast to the present
results, Enoki et al. (2006) [50] observed decreased MCT1 protein expression in the heart with
testosterone treatment suggesting that regulation of MCT1 by testosterone varies by tissue.
Increased membrane MCT1 membrane in males may result in increased hepatic uptake of MCT1
substrates, and future studies should evaluate hepatic transport of MCT1 substrates.
Testosterone-mediated increases in MCT4 mRNA and protein expression have been
demonstrated in rat muscle with no correlation between mRNA and protein consistent with
testosterone-mediated regulation of muscle MCT1 [50]. In Sertoli cells, MCT4 mRNA
expression did not differ from control when the cells were treated with estradiol or testosterone
[108]; however, Rato et al. (2012) [51] demonstrated decreases in MCT4 mRNA expression
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with testosterone treatment for 50 hours. We observed a significant difference in MCT4 mRNA
expression between groups (P = 0.0088) with females of all estrous stages having lower
expression than males and OVX females. However, we observed no difference from males with
respect to total cellular protein expression in females over the estrous cycle or in the absence of
female sex hormones. A significant difference was observed between groups for membrane
MCT4 expression (P = 0.0186) with all females having lower expression than males. Proestrus
females had significantly lower membrane MCT4 expression as compared to males (post-hoc
comparison). Membrane MCT4 expression did not differ between ovariectomized females and
any of the estrous cycle stages suggesting that the membrane trafficking differences between
males and females were mediated by testosterone. MCT4 is thought to function as an efflux
transporter, therefore increased expression in males may result in decreased intracellular
accumulation of MCT4 substrates in hepatocytes. Accumulation of compounds that are
substrates of both MCT1 (uptake transporter) and MCT4 will be governed by the transporter
with the highest abundance, which in the case of the liver is MCT1.
CD147, an ancillary protein for MCT1 and MCT4, is involved in their membrane
trafficking, thus contributing to the amount of functional transporter in a given tissue. Previous
studies have evaluated the role of estrogen receptors (ER) in CD147 regulation in reproductive
tissues utilizing knock out mice, with ERα dependent regulation in the uterus and efferent ducts,
and ER-independent regulation in other tissues [109]. There is a paucity of information in the
literature on sex hormone-mediated regulation of CD147 in tissues involved in drug disposition.
We have demonstrated differences in membrane expression of CD147, with males having higher
expression than females, in the presence or absence of female sex hormones. No differences
were observed in mRNA or total cellular protein expression of CD147 suggesting that
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testosterone plays a role in membrane trafficking and/or post-translational regulation. CD147
membrane expression correlated significantly with MCT4 membrane expression in all animals,
while CD147 and MCT1 membrane expression showed a significant correlation when OVX
females were removed from the analysis. These results suggest that both testosterone and female
sex hormones may be involved in the regulation of membrane expression, and therefore
functional MCT-mediated transport in the liver.
In summary, we have demonstrated sex-hormone dependent regulation of MCT1 and
MCT4 in the liver. MCT1 mRNA and protein expression demonstrated differences with estrous
cycle stage and in the absence of female sex hormones, while MCT4 and CD147 membrane
expression were independent of the estrous cycle and may be regulated by testosterone. Further
studies are necessary to comprehensively evaluate the mechanisms underlying the sex hormonedependent regulation of membrane expression of MCTs in hepatocytes, as well as the influence
on substrate transport kinetics to predict the impact on hepatic drug disposition and
pharmacokinetics.
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Chapter 4: Spatial and Sex Differences in the Intestinal Expression of Monocarboxylate
Transporters

4.1 Introduction
Intestinal tissues serve as an important organ with conserved function in vertebrate
animal physiology. The epithelial cells of intestinal tissue segments are critical sites for the
absorption and metabolism of nutrients and exogenous compounds. Bacteria in the human
intestine can ferment carbohydrates and dietary fibers ingested in the diet [110]. The fermented
products include short chain fatty acid such as pyruvate, butyrate and acetate [111]. These
monocarboxylates are transported into intestinal epithelial cells by monocarboxylate transporters
[112, 113]. Tissues can then consume the absorbed monocarboxylates as an energy source.
Compared to energy sources such as glucose, monocarboxylates provide a limited amount of
energy; however, under specific conditions, such as low oxygen and starvation, these nutrients
can be very important energy sources [114].
In addition to nutrient absorption, monocarboxylate transporters are important absorption
routes for small monocarboxylate drugs. There are many factors influencing drug bioavailability
(the fraction of drug that reaches systemic circulation) when it comes to oral drug administration.
The dosage form, solubility, intestinal motility, intestinal pH, intestinal water content, intestinal
and hepatic metabolizing enzymes, and drug transporters are important factors influencing drug
bioavailability. Among these factors, drug transporters play an essential role in altering drug
bioavailability through alterations in intestinal uptake, and are commonly studied in drug
development research [115]. For drugs such as valproic acid, GHB, and nicotinic acid, salicylic
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acid, β‐lactam antibiotics, and some statins, their bioavailability may be influenced by the
expression of monocarboxylate transporters [116].
Proton-coupled monocarboxylate transporters belongs to the SLC family and there are 14
isoforms identified so far. Different isoforms have distinct distribution along the human
intestine. MCT1 is the predominantly expressed isoform among the MCT family. MCT1 is
expressed along the intestinal tract: mRNA and membrane protein expression increases along the
human intestinal tract with the highest expression in the ileum and colon [83]. Immunostaining
and immunoblotting have demonstrated that MCT1 is expressed on the apical side of the
intestinal membrane, consistent with expression in Caco-2 cell lines [117]. MCT1 has also been
demonstrated to be expressed in the basolateral side of the intestine in rats, mice and humans
[118]. MCT4 is expressed in human intestine [119]. The expression pattern of MCT4
membrane protein is similar to MCT1 with expression increasing along the small intestinal tract.
MCT4 is primarily expressed in the basolateral membrane with an overall lower expression as
compared to MCT1. MCT5 (SLC16A4) expression occurs in the human intestine basolateral
membrane; however, substrates of this transporter have yet to be identified [83]. SMCT1
(SLC5A8) transports small monocarboxylates in a sodium coupled manner. Intestinal expression
of SMCT1 was identified in the mouse jejunum and ileum on the apical side of the membrane in
an immunofluorescence localization study [120]. SMCT2 mRNA was found expressed in mouse
small intestine predominantly in jejunum [114]. There is no human intestinal expression data
thus far for SMCT1 and SMCT2.
Monocarboxylate transporters are responsible for the uptake of nutrients such as short
chain fatty acids in to the body. The absorption of monocarboxylate drug are mediated by MCTs
and SMCTs. The expression level of these transporters is an important factor influencing drug
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absorption and bioavailability. Increased monocarboxylate transporter expression in the
intestinal enterocyte membrane may result in increased oral absorption of the drug, leading to
higher plasma concentrations. Given the same dosage to a patient with higher intestinal
MCT/SMCT expression may lead to higher chance for drug toxicity due to increased drug
exposure. Similarly, if a patient had lower intestinal MCTs expression, the same dosage may
lead to a lack of drug efficacy.
4.2 Chapter Objectives
It is of vital importance to understand the drug absorption during oral drug development
processes. Characterizing transporter expression patterns in the gastrointestinal track would
greatly contribute to our understanding of factors that influence substrate drug pharmacokinetics.
Monocarboxylate transporters are regulated by sex hormones in tissues, such as liver, skeletal
muscles and Sertoli cells [50, 51, 121]. However, currently no studies have evaluated whether
MCTs and SMCTs demonstrate sex and estrous cycle differences in the small intestine.
Quantitative data on MCT/SMCT protein and mRNA expression in the three small intestinal
sections in rats is not available in the literature.
The aim of the current study was to elucidate whether intestinal MCTs, SMCTs and
CD147 are regulated by sex hormones, and whether these regulation mechanisms are region
specific. Our hypothesis is that monocarboxylate transporters and CD147 expression varies
between intestinal segments (duodenum, jejunum and ileum) and expression is regulated by sex
hormone in rats. Monocarboxylate transporters (MCT1, MCT4 and SMCT1) and CD147
expression was quantified in three intestinal segments: duodenum, jejunum and ileum.
Expression was evaluated in six groups of rats: the four female estrus stages, ovariectomized
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females, and male SD rats. mRNA and membrane protein expression were analyzed by real time
PCR and western blot. Study design and quantitative analysis are described in Chapter 2.
4.3 Data Analysis
mRNA expression is expressed as mean ± standard error of the mean. Protein data are
expressed as mean ± standard deviation. Expression of mRNA was normalized to the mean of
the house-keeping genes, 18S and alien RNA, and fold-change was determined using the ∆∆CT
method. MCT1, SMCT1 and CD147 membrane protein expression was normalized to total
loaded protein. Data was analyzed in GraphPad Prism 6 using one-way analysis of variance
(ANOVA) with a Tukey’s post hoc test. It was considered statistically significant when the p
value was less than 0.05.
4.4 Results
4.4.1 Spatial and sex differences in mRNA expression. qPCR results demonstrate that
there are mRNA expression differences between different segments of the small intestine (Figure
4.1). The overall expression level of MCT1, MCT4, SMCT1 and CD147 was higher in the ileum
and lowest in the duodenum (Figure 4.1). MCT1 and MCT4 expression varied significantly with
intestinal region (P < 0.0001 and P = 0.0006) and sex (P = 0.0167 and P = 0.0011).
Interestingly, males had the highest MCT1 and MCT4 in the jejunum. SMCT1 expression varied
significantly with intestinal region (P < 0.0001). Duodenum SMCT1 expression was much
lower compared to ileum (Figure 4.1C); however, there was a large amount of variability in the
ileum. CD147 mRNA expression varied significantly with intestinal region (P < 0.0001) and sex
(P = 0.0167).
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mRNA expression in the duodenum in presented in Figure 4.2. MCT1 expression varied
over the estrus cycle and between sexes (P = 0.0691), with the lowest expression in proestrus
females, whose expression was also lower than OVX females and males (Figure 4.2A). MCT4
mRNA expression trended higher in OVX females and male compared to the estrus female
groups with no differences between the cycling females (Figure 4.2B). The mRNA expression
of SMCT1 was lower in OVX females and males with some variability over the estrus cycle
(Figure 4.2C). No significant differences were observed for CD147 expression. MCT4,
SMCT1, and CD147 mRNA expression did not demonstrated any significant differences
between the sexes or over the estrus cycle (P values for one-way ANOVA were all greater than
0.25).
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Figure 4.1: Spatial mRNA expression of MCT1, MCT4, SMCT1 and CD147 in
intestinal tissue. MCT1, MCT4 and CD147 fold changes are relative to jejunum male
group. SMCT1 fold changes are relative to duodenum proestrus group MCT1, MCT4,
SMCT1 and CD147 was normalized to Alien RNA. Data presented as mean + SEM.
(n=3-5 rats)
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Figure 4.2: MCT1, MCT4, SMCT1, CD147 mRNA expression in duodenum. Bar
graph represent starting quantity (SQ) of MCT1, MCT4, SMCT1, CD147 normalized
to SQ of 18s. Data presented as mean + SEM. (n=3-5 rats) Pro: proestrus. Es: estrus
group. Me: metestrus group. Di: diestrus group. OVX: ovariectomized group.

mRNA expression in the jejunum is presented in Figure 4.3. MCT1 mRNA expression in
the jejunum demonstrated significant differences between males and females including OVX
females (P = 0.0061) (Figure 4.3A). Males had significantly higher MCT1 expression when
compared to proestrus, estrus, diestrus and OVX females. This indicates that male sex hormones
may contribute to the higher MCT1 mRNA expression. MCT4 expression in the jejunum varied
between groups (P = 0.0504) with higher expression in both males and OVX females compared
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to all cycling females suggesting that female sex hormones may negatively regulate MCT4
mRNA expression (Figure 4.3B). SMCT1 expression was highly variable in the jejunum (Figure
4.3C). CD147 expression in the jejunum varied significantly between groups (P = 0.0059).

Figure 4.3: MCT1, MCT4, SMCT1, CD147 mRNA expression in jejunum. Bar graph
represent starting quantity (SQ) of MCT1, MCT4, SMCT1, CD147 normalized to SQ
of 18s. * p<0.05 compared to male group. Data presented as mean + SEM. (n=3-5
rats). Pro: proestrus. Es: estrus group. Me: metestrus group. Di: diestrus group. OVX:
ovariectomized group.
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The CD147 expression pattern was similar to the MCT1 expression in the jejunum with
proestrus, estrus and diestrus females having significantly lower CD147 expression compared to
males (Figure 4.3D). Metestrus and OVX females, although not statistically significant, trended
lower compared to males (Figure 4.3D).
mRNA expression in the ileum is presented in Figure 4.4. MCT1 did not demonstrated
any differences in the ileum with relatively higher mRNA expression in diestrus group (Figure
4.4A). MCT4 expression in the ileum varied significantly between groups (P = 0.001). OVX
females had significantly higher expression of MCT4 mRNA in the ileum compared to other
female and male rats (Figure 4.4B). This suggests that removal of female sex hormones plays a
role in MCT4 regulation in the ileum. Male rats had relatively higher MCT4 expression
compared to the cycling females. This expression pattern is consistent with other segments of
the small intestine where MCT4 mRNA had higher expression in males and OVX females. This
indicates that female hormones act the same for MCT4 mRNA along the small intestinal tract.
SMCT1 and CD147 did not have any differences among the six groups of animals in the ileum.
SMCT1 had lower expression in male rats compared with all the other female groups including
OVX groups (Figure 4.4C). CD147 demonstrated increased mRNA expression in the OVX
group compared to female groups (Figure 4.4D).
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Figure 4.4: MCT1, MCT4, SMCT1, CD147 mRNA expression in ileum. Bar graph
represent starting quantity (SQ) of MCT1, MCT4, SMCT1, CD147 normalized to SQ
of 18s. # p<0.05 compared to OVX group. Data presented as mean + SEM. (n=3-5
rats). Pro: proestrus. Es: estrus group. Me: metestrus group. Di: diestrus group. OVX:
ovariectomized group.

4.4.2 Spatial differences in membrane protein expression. Membrane MCT1
expression was too low to be detected in the duodenum by western blot (Figure 4.5A). MCT1
membrane expression in the ileum was detectable in approximately 40% of samples; some of the
samples had no detectable MCT1 expression while others had higher expression causing large
variability within each group (Figure 4.5B). MCT4 protein expression was low in both
duodenum and ileum. Jejunum membrane protein was were not successfully extracted,
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determined by poor Na+/K+ ATPase membrane protein enrichment. Therefore, we were only
able to quantify SMCT1 and CD147 membrane protein expression.

Figure 4.5: Representative MCT1 western blot. A. MCT1 membrane expression in the duodenum.
B. MCT1 membrane expression in the ileum. 5μg membrane protein was loaded to each lane.
Thirteen membrane protein samples were loaded each gel.

There were no differences in membrane SMCT1 and CD147 expression between the
sexes or over the estrus cycle in females in duodenum (P = 0.6926 and P = 0.9519) and ileum (P
= 0.2445 and P = 0.1087). SMCT1 membrane protein expression in the OVX females trended
lower compared to males and cycling females in duodenum (Figure 4.6A). CD147 membrane
protein expression had the same pattern as mRNA expression illustrating that sex hormones do
not alter CD147 expression in rat small intestine tisses (Figure 4.6B, 4.7).
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Figure 4.6: SMCT1 and CD147 membrane bound protein expression in duodenum. A.
SMCT1 membrane protein expression. B. CD147 membrane protein expression. Data
normalized to total loaded protein. Data presented as mean ± SD. (n = 4 - 5 rats).
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Figure 4.7: SMCT1 and CD147 membrane bound protein expression in ileum. A. SMCT1
membrane protein expression. B. CD147 membrane protein expression. Data normalized to
total loaded protein. Data presented as mean ± SD. (n = 4 - 5 rats).
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4.5 Discussion
The current study aims to evaluate sex and sex hormone-dependent regulation of
monocarboxylate transporters and their ancillary protein CD147 in the three small intestinal
regions. We have for the first time demonstrated that monocarboxylate transporters and CD147
mRNA expression was different and increased along the small intestinal segments with highest
mRNA level in ileum. MCT1, MCT4 and CD147 mRNA expression were regulated by sex
hormone in the three intestinal regions. Membrane protein of CD147 and SMCT1 was not
influenced by sex hormones. We were unable to detect, and therefore quantify, MCT1 and
MCT4 protein expression.
The mRNA expression trends observed were consistent with the findings of human
intestinal MCT1 membrane protein and RNA expression, with the expression level increased
along the small intestine [83]. Among the three regions, ileum had highest mRNA expression of
monocarboxylate transporters and CD147. MCT1 mRNA showed differences over the estrus
cycle and between sexes in jejunum. Male rats had higher mRNA expression compared to
female groups. This is consistent with sex-dependent expression of MCT1 in the liver where
male had greater expression compared to cycling females [121]. Previous studies in skeletal
muscle indicated that testosterone increased muscle MCT1 mRNA expression, but this regulation
was specific to muscle type [50]. Consistent with this observation, the alteration in MCT1
mRNA was region specific because MCT1 mRNA expression was not different between sexes in
the duodenum and ileum.
MCT4 mRNA expression was significantly higher when female sex hormones were
removed via ovariectomy. MCT4 mRNA expression had the same pattern in all three segments
of the intestine with higher expression in males and OVX females compared to cycling females
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suggesting that female hormones down regulated MCT4 mRNA expression in the intestine.
Previous studies have shown that 17β-estradiol treatment on rat Sertoli cells decreased MCT4
mRNA expression level [51]. Testosterone treated rat skeletal muscle had increased MCT4
mRNA expression [50]. These results suggesting that MCT4 expression was regulated by
different sex hormones in each tissue or was regulated by more than one sex hormone.
When it comes to protein expression, there were difficulties extracting intact total and
membrane protein due to the complicated and enzyme rich environment of intestinal tissue.
Through optimization of the membrane extraction method, membrane bound protein was
successfully extracted in the duodenum and ileum (refer to Chapter 2). MCT1 protein
expression was too low to be detected in the majority of samples with only a few ileum samples
visible on western blot images (Figure 4.5). MCT4 protein expression was not detectable in all
samples. Both the MCT1 and MCT4 antibodies are polyclonal, and evaluation of other
antibodies may be necessary to improve detection. Immunohistochemistry could potentially be
used in the future to evaluate expression in intestinal regions, as well as membrane localization.
SMCT1 and CD147 expression were evaluated in the duodenum and ileum, with no significant
differences in the membrane protein expression of either protein.
In the present study we were unable to quantify total cellular protein expression which
limits our understanding of MCT/SMCT and CD147 translation regulation and membrane
trafficking. We are unable to determine if the transporters are regulated by sex hormones
through post-transcriptional or translational mechanisms. Future studies need to be conducted to
optimize the extraction of total cellular and membrane proteins from intestinal enterocytes to
provide a more complete picture of MCT/SMCT regulatory pathways in the intestine.
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We have demonstrated the sex hormones regulate mRNA expression of MCT1 and
MCT4 in a regional manner, while SMCT1 expression varies with intestinal region. SMCT1 and
CD147 membrane expression did not vary over the estrus cycle or between sexes in the
duodenum and ileum. Whether intestinal MCT1 and MCT4 membrane protein expression are
regulated by sex hormone is still not clear. There is a need to develop a new method with higher
sensitivity to evaluate their protein expression in intestinal tissue. Sex hormone-dependent
transcriptional regulation mechanisms of MCT1 and MCT4 still need to be elucidated. In vitro
experiments should be conducted to evaluate the contribution of individual sex hormones to
MCT1 and MCT4 regulation, and whether these mechanisms are sex hormone receptor
dependent. In addition, functional studies should be conducted to evaluate intestinal transport of
MCT/SMCT substrates to determine whether transport capacity is influenced by the estrus cycle
or the removal of sex hormones.
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Chapter 5: Regulation of Renal Monocarboxylate Transporters by Sex Hormones

5.1 Introduction
The kidney plays an important role in maintaining body homeostasis through filtration,
reabsorption, secretion and urinary excretion of endogenous and exogenous compounds. The
kidney participates in the control of body acid-base balance, body fluid osmolality, blood
pressure, and volume of body fluids. The functional unit of the kidney is the nephron with
around 1.3 million nephrons in each healthy adult kidney [122]. Glomeruli and renal tubules are
the functional components of the nephron involved in systemic drug clearance. The glomerulus
contributes to filtration clearance with small molecules being filtered into the tubular lumen,
while large molecules such as proteins (more than 30kD) and cells being retained in the
circulatory system. Essential nutrients such as glucose and amino acids are reabsorbed through
renal tubules. Water and ions are reabsorbed along the length of the nephron. After filtration,
secretion and reabsorption, urine is eventually produced and eliminated out of the body [123].
Through this process, the kidney is able to conserve indispensable nutrients, and get rid of
metabolic waste products and exogenous compounds. The renal tubule is composed of three
segments: the proximal tubule, the loop of Henle, and the distal tubule. Membrane transporters
on the monolayer of the tubule epithelial cells play a vital role in active reabsorption and
secretion clearance of exogenous compounds [124].
Monocarboxylate transporters are one of the membrane transporter families that
participate in renal tubule functions. Both proton (MCT) and sodium (SMCT) dependent
monocarboxylate transporters are expressed in the proximal renal tubules [7, 22, 35]. There are
14 members in the proton-dependent monocarboxylate transporter family (SLC16) and some of
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the isoforms can be found in the kidney. MCT1 protein expression was identified in the
basolateral membrane of the mouse kidney proximal tubule via immunohistochemical staining
[22], which is consistent with localization of MCT1 expression in rat and human cells [20, 125].
MCT2 is localized to the basolateral membrane of the thick ascending limb of the loop of Henle
[15, 22]. MCT4 is expressed on the basolateral membrane of renal proximal tubules [23]. Only
two members of the SMCT family had been identified and both of them are expressed in kidney
proximal tubule cells. SMCT1 is located in the S3 segment of proximal tubule, while SMCT2 is
expressed in the entire length of the proximal tubule in mouse kidney [34, 120]. SMCTs are
primarily expressed in the renal apical membrane at the cellular level [31, 34].
Monocarboxylate transporters are involved in reabsorption of short chain fatty acids,
ketone bodies and monocarboxylate drugs [12, 20, 126, 127]. Based on their different membrane
localization, MCTs and SMCTs co-operate in nutrient and drug reabsorption in the kidney. It
has been demonstrated that kidney proximal tubule cells reabsorb lactate via SMCT1 at the
apical membrane [34]. In the HK-2 cell line, MCT1 is expressed on the basolateral membrane
and mediates substrate efflux from the epithelial cells to blood circulation [20, 127]. The
reabsorption is accomplished by MCT1 /SMCT1 located at each side of the proximal tubule
membrane. In this case, if MCT1/ SMCT1 expression on the cellular membrane is increased, the
reabsorption of the substrate drugs such as GHB and valproic acid would be increased.
MCT/SMCT substrate drugs would stay in the circulation longer and clearance would be
decreased. In other words, if the transporter membrane expression is higher in certain
populations, the same dosage would lead to higher chance of toxicity than other populations with
lower transporter expression. In contrast, lower renal membrane expression of MCT1/SMCT1
proteins would lead to higher renal clearance and lower substrate drug efficacy. Alterations in
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MCT/SMCT expression can impact the renal clearance of substrates. A better understanding of
the transporter expression is needed in drug development and toxicokinetic studies.
5.2 Chapter Objectives
It had been demonstrated that monocarboxylate transporters and their ancillary protein,
CD147, are regulated by sex hormones in a tissue specific manner. Chapter 3 demonstrated that
monocarboxylate transporters are regulated by sex hormones in rat liver. Testosterone regulates
MCT1 and MCT4 expression in rat skeletal muscle [50]. There is no literature data evaluating if
renal monocarboxylate transporters are regulated by sex hormones or differ between sexes.
Studying hormonal regulation of renal monocarboxylate transporters would give us a better
understanding of nutrient and drug elimination in the kidney.
We hypothesize that monocarboxylate transporters and CD147 expression are different
between sexes and are regulated by sex hormones. In the current study, renal expression of
MCTs, SMCTs and CD147 was evaluated in over the estrus cycle in females, in males, and in
the absence of female (OVX, ovariectomized) or male hormones (CST, castrated) SpragueDawley rats. mRNA was quantified by real-time qPCR. Total protein and membrane protein
were evaluated by western blot. Methods and method optimization were discussed in Chapter 2.
5.3 Data Analysis
Data are expressed as mean ± standard deviation. Expression of mRNA was normalized to
the mean of house-keeping gene 18S and alien RNA, and fold-change was determined using the
∆∆CT method. MCT1, SMCT1 and CD147 protein expression was normalized to GAPDH.
MCT1, SMCT1 and CD147 membrane protein expression was normalized to Na+/K+ ATPase
expression. Data was analyzed in GraphPad Prism 6 using a one-way analysis of variance

101

(ANOVA) with a Tukey’s post hoc test. Differences were considered statistically significant
when the p value was less than 0.05.
5.4 Results
5.4.1 Estrus staging. Female estrus groups were accessed by vaginal lavage smears. The
representative estrus stage evaluation results were discussed in Chapter 2.
5.4.2 MCT1 expression. MCT1 mRNA expression varied significantly between groups
(P = 0.0049). MCT1 mRNA expression was significantly higher in male rats compared to the
other groups, including castrated males. Male rats had 20 to 40 fold higher expression compared
to female estrus cycle groups. Compared to OVX groups, males had around 90-fold higher mRNA
expression levels. MCT1 mRNA differences indicate that sex plays a significant role in MCT1
expression. There were no significant differences in mRNA expression between cycling females
and OVX females (Figure 5.1 A); however, OVX females trended lower than females exposed to
sex hormones. Whole cell MCT1 protein expression (Figure 5.1B) was highly variable within the
groups with metestrus and diestrus females having similar expression levels to CST males.
Membrane MCT1 expressed varied significantly between groups (P = 0.0457). Proestrus and
metestrus females demonstrated significantly lower MCT1 membrane protein expression
compared to CST males and had lower expression than other cycling and OVX females (Figure
5.1C). Estrus, diestrus OVX females had lower MCT1 membrane expression as compared to CST
rats with estrus females having the highest expression of any female. CST male rats expressed
approximately twice as much MCT1 membrane expression as compared to males.
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Figure 5.1: MCT1 mRNA, whole cell and membrane bound protein expression in
kidney. A. Fold-change in MCT1 mRNA in rat kidney. B. Whole cell MCT1 protein
expression in kidney with expression normalized to GAPDH expression. C. MCT1
membrane protein expression with expression normalized to Na+/K+ ATPase
expression. Data presented as mean ± SD. *p < 0.05 compared to male group. #p <
0.05 compared to CST group. (n = 4 - 5 rats).
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5.4.3 MCT4 expression. MCT4 mRNA expression was analyzed using qPCR and did not
demonstrated any significant differences among the tested groups (P = 0.147); however,
expression in CST males did trend lower than the other groups (Figure 5.2). Whole cell protein
and membrane protein expression was too low to be detected.

Figure 5.2: MCT4 mRNA expression. MCT4 mRNA fold-change in rat kidney. Data
presented as mean ± SD. (n = 4 - 5 rats).
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Figure 5.3: SMCT1 mRNA, whole cell and membrane bound protein expression in
kidney. A. Fold-change in MCT1 mRNA in rat kidney. B. Whole cell MCT1 protein
expression in kidney. Data normalized to GAPDH expression. C. MCT1 membrane
protein expression. Data normalized to Na+/K+ ATPase expression. Data presented as
mean ± SD. *p < 0.05 compared to male group. #p < 0.05 compared to CST group. (n
= 4 - 5 rats).
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5.4.4 SMCT1 expression. Expression of SMCT1 is presented in Figure 5.3. There was
no significant differences in SMCT1 mRNA expression between sexes, over the estrus cycle stages,
or between males and castrated rats (P = 0.6316). Similarly, whole cell protein expression did not
show any difference between sexes, CST males or OVX females (P = 0.376). SMCT1 membrane
expression was not statistically different between groups (P = 0.0762); however, this may be due
to the large variability in each group and the animal number used. SMCT1 membrane expression
trends higher in male and CST male rats suggesting that a mechanism unrelated tosex hormones
may be involved.
5.4.5 CD147 expression. mRNA of the ancillary protein CD147 did not demonstrate any
differences between groups (P = 0.267) with a similar result observed for CD147 whole cell protein
expression (P = 0.5870). However, membrane CD147 protein expression demonstrated significant
differences between groups (P = 0.0008). CST males demonstrated significantly higher membrane
CD147 expression compared to males and OVX females. CST males had significantly higher
membrane CD147 versus all cycling females except proestrus females. Removal of androgens
altered CD147 membrane localization significantly. OVX trended higher than estrus, metestrus
and diestrus females, and were comparable to intact males; however, these differences were not
statistically significant.
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Figure 5.4: CD147 mRNA, whole cell and membrane bound protein expression in
kidney. A. Fold-change in CD147 mRNA in rat kidney. B. Whole cell CD147 protein
expression in kidney. Data normalized to GAPDH expression C. CD147 membrane
protein expression. Data normalized to Na+/K+ ATPase expression, and presented as
mean ± SD. #p < 0.05 compared to CST group. (n = 4 - 5 rats).
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5.5 Discussion
Monocarboxylate transporters are involved in nutrient and drug distribution in the
kidney. MCTs and SMCTs are important for maintaining kidney functions. Alterations in renal
monocarboxylate transporter expression could lead to changes in nutrient reabsorption, drug
reabsorption and renal clearance. Previous studies have been demonstrated that
monocarboxylate transporters are regulated in a tissue specific manner by sex hormones [50, 51,
121]. We have previously demonstrated that monocarboxylate transporters are regulated by sex
hormones in the liver and intestine (Chapters 3 & 4). However, no studies have investigated if
renal monocarboxylate transporters are regulated by sex hormones. This study for the first time
analyzed the influence of the estrus cycle and removal of both male and female sex hormones on
the regulation of monocarboxylate transporters and CD147 in the kidney. In the current study,
transporter expression was evaluated in rats under different sex hormone conditions. Female
hormones fluctuate along the progression of the estrus cycle and OVX females represent female
rats with removal ovarian hormones (estrogen and progesterone). CST males represent male rats
with removal of testosterone. Both OVX and CST surgeries were performed after sexual
maturity, so they were exposed to sex specific hormones prior to surgery.
MCT1 mRNA was significantly higher in male rats compared to all female groups. This
indicates that androgens might plays a role in the increased MCT1 mRNA expression. This is
also supported by the decreased mRNA expression when androgens are absent in the CST group.
However, MCT1 total protein did not demonstrated differences among the seven experimental
groups. This suggests that post-transcriptional regulation mechanisms may govern total MCT1
expression in the kidney. In contrast, MCT1 membrane expression demonstrated differences in
cycling female groups. Estrus females expressed higher membrane MCT1 versus proestrus and
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metestrus females indicating fluctuating female sex hormones contribute to membrane MCT1
expression. MCT1 membrane expression in CST males was higher compared to all the other
groups indicating that removal of androgens contributes to MCT1 membrane localization.
Different expression patterns between total MCT1 and membrane MCT1 expression illustrated
that hormones may be involved in the regulation MCT1 membrane localization. This is
consistent with previous literature that total MCT1 protein expression decreased with
testosterone treatment in the heart [50]. In contrast to the results in the kidney, testosterone
treatment elevated MCT1 protein expression in rat skeletal muscle [50], which supports our
hypothesis thatMCT1 is regulated by sex hormones in a tissue specific manner.
As mentioned in the chapter 3, MCT4 protein and mRNA expression was low in liver. A
similar phenomenon was observed in the kidney. mRNA was detectable, but there was no
difference between groups. Whole cell and membrane MCT4 expression was not detectable via
western blot. MCT4 protein expression has been detected in human kidney [13] and rat kidney
KNRK cells (unpublished data, Felmlee lab). Previous studies have indicated that MCT4 protein
in rat kidney was not detectable via western blot, but mRNA was detected [128, 129]. Our
observations are consistent with previous results; however, a different antibody or proteomic
LC/MS/MS analysis may allow for detection in the future.
SMCT1 had similar expression pattern in mRNA, total protein and membrane protein
expression levels. Different hormone conditions did not affect SMCT1 expression. This is
consistent with our results in intestinal tissues. Previous study in mice indicated that castration
decreased SMCT1 expression in the kidney, and testosterone treatment increased the SMCT1
protein and mRNA expression [54]. The differences between these studies suggests that
regulation of SMCT1 by sex hormones may differ between species.
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CD147 expression was not significantly different between the sexes and in the absence of
sex hormones with respect to mRNA and total protein expression. Membrane CD147 expression
demonstrated significant differences between the sexes and over the estrus cycle. Estrus,
metestrus and diestrus females had significantly lower expression levels compared to castrated
rats. Proestrus females had higher CD147 membrane expression compared to other cycling
females. These expression differences suggest that androgens play a vital role in CD147
membrane localization. In Chapter 3, CD147 mRNA expression in the jejunum was
significantly different between the sexes and over the estrus cycle; however, we could not
quantify CD147 membrane expression in the jejunum due to difficulties in isolating the
membrane fraction. CD147 mRNA expression was higher in ERα knockout mice compared with
WT and ERβ knockout mice indicating estrogen can regulate CD147 expression [109].
Interestingly, MCT1 membrane expression had similar pattern with membrane CD147
expression suggesting that CD147 could contribute to MCT1 membrane trafficking.
Renal clearance of monocarboxylate transporter substrates are affected by transporter
expression levels [130]. Based on the current data, it can be concluded that MCT1 is regulated
by sex hormone in the kidney and SMCT1 varied between groups, but did not demonstrated
significant differences. Active renal reabsorption via monocarboxylate transporters in the renal
proximal tubule may be altered under different sex hormone conditions leading to altered renal
clearance. MCT1 and SMCT1 both contribute to changes in renal reabsorption and clearance.
With lower membrane MCT1 protein expression, reabsorption in the kidney tubule would be
decreased, leading to higher renal clearance of monocarboxylate transporter substrates. Previous
data from our lab have shown that proestrus females have higher renal clearance of GHB (an
MCT and SMCT substrate) compared to OVX females and males. This could be result of the
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lower MCT1 membrane protein expression in proestrus females; however, we cannot conclude
that the different renal clearance values between cycling females, OVX females and males are
determined by MCT1 membrane expression alone. There are other transporters including
MCT4, SMCT1 and SMCT2. SMCT1 demonstrated no significant differences in membrane
protein expression in the current study, but trended higher in male and CST rats (Figure 5.3C),
which is consistent with the lower GHB renal clearance observed in males. In the current study,
apical membrane localized protein SMCT2 was not evaluated, and should be quantified in future
studies. MCT4 membrane expression was not detectable in the current study; a more sensitive
antibody or a proteomic LC/MS/MS approach should be evaluated in the future.
In summary, this chapter demonstrated that renal MCT1 and CD147 expression were
altered over the estrus cycle in females and in the absence of male and female sex hormones.
MCT4 protein expression was no detectable in the kidney. SMCT1 mRNA and protein

Figure 5.5: GHB renal clearance over the estrus cycle, in OVX females and male rats.
* p < 0.05 compared to proestrus group. #p < 0.05 compared to Estrus group. (Data
from Hao Wei, MS thesis)
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expression did not vary between sexes or over the estrus cycle. Studies evaluating the role of
individual sex hormones are needed to illustrate which sex hormones are regulating
monocarboxylate transporter and CD147 expression. In vitro studies with a kidney cell line
could be used as a screening tool to identify which specific sex hormones are regulating renal
monocarboxylate transporters. Hormonal replacement experiment could be conducted to see if
testosterone, estradiol or progesterone are responsible for the observed differences in transporter
expression.
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Chapter 6: Renal Monocarboxylate Transporter Expression in Response to Sex Hormone
Replacement

6.1 Introduction
As observed in previous chapters, monocarboxylate transporters and ancillary protein
expression levels vary between female estrus cycle groups and between sexes. In addition, there
are alterations in transporter expression with the removal of male or female sex hormones
through castration or ovariectomy. Sex hormone treatment has the potential to regulate
monocarboxylate transporters. Testosterone treatment has been demonstrated to upregulate
MCT2 mRNA expression in rat Sertoli cells [51], and increased rat skeletal muscle MCT1 and
MCT4 expression [50]. In castrated mice, treatment with 2.5 mg/kg testosterone treatment for 8
days elevated mouse kidney SMCT1 protein and mRNA expression [54]. Besides testosterone,
estrogen also demonstrates regulatory effects on monocarboxylate transporters. Rat Sertoli cells
treated with 17β-estradiol had decreased MCT4 mRNA expression [51]. Inhibition of the ERRalpha receptor down regulated MCT1 expression in breast cancer baring mice [38]. MCT2
protein expression in the brain was increased after ovariectomy, and this phenomenon was
attenuated by administration of 17β-estradiol [131].
Besides natural hormone fluctuation in women and sex hormone differences between
sexes, there are patient that need hormone replacement therapy to improve quality of life.
Hormone replacement therapy for women consists of treatment with estrogen alone or estrogen
with progesterone to restore normal physiological hormone levels for women who experienced
menopause or hysterectomy. During menopause women may experience hot flashes, sleep
disorders and mood swings due to changes in sex hormone levels [132]. Hormone replacement
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therapy is needed because estrogen and progesterone production are reduced to a level that
influences a patient’s quality of life. Testosterone therapy is available for patients with
decreased testosterone levels with aging [133]. By administering testosterone, symptoms such as
low sex drive, fatigue, lower muscle mass and depression can be attenuated [133, 134].
Transporter expression in these patients could be affected by hormone replacement therapy.
Variation in sex hormone levels may alter monocarboxylate transporter expression leading to
other drug disposition changes. Nutrient homeostasis may be altered as well. There is currently
an absence of information in the literature evaluating the impact of sex hormones and sex
hormone replacement on monocarboxylate transporter expression in drug distribution tissues.
In this study, ovariectomized female and castrated male rats were used as animal models
to investigate if testosterone and 17β-estradiol regulate MCTs, SMCTs and CD147.
Ovariectomy is the surgery of removing ovaries, and it is a common animal model for female sex
hormone related studies [131, 135, 136]. Ovariectomy results in removal of the female sex
hormones, estrogen and progesterone. It is widely used in studies evaluating the impact of sex
hormones on various disease states including osteoarthritis, osteoporosis and obesity [136, 137].
Castration, removal of the male testicles, is a representative animal model to study the effect of
male sex hormones. Castration results in the removal of male sex hormones, testosterone and
dihydrotestosterone. It is commonly used in studies related to androgen regulation of
physiological processes [138-140].
6.2 Chapter Objective
Monocarboxylate transporters demonstrated sex and estrus cycle differences in
expression in drug distribution tissues as discussed in previous chapters. Specifically, kidney
monocarboxylate transporters varied over the estrus cycle and between sexes. However, the sex
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hormones regulating these changes in MCT/SMCT expression have not been identified. We
hypothesize that testosterone and 17β-estradiol replacement will alter monocarboxylate
transporter expression in rat kidney. In this study, ovariectomized female and castrated male SD
rats were used to investigate renal MCT and SMCT expression following testosterone and 17βestradiol treatment.
In the current study, OVX females and CST males were used as sex hormone exposure is
eliminated after surgery. Hormone or vehicle treatment was initiated two weeks after surgery.
OVX females were separated into two groups (n= 6), one of the groups as vehicle control, the
other one was treated with 17β – estradiol (1.5 mg of estradiol with a 60-day release pellet).
CST males were separated into testosterone (3 mg/kg/day for 14 days) and vehicle treated
groups. Treatment, tissue collection and sample analysis were described in the method section
(Chapter 2).
6.3 Data Analysis
Data are expressed as mean ± standard deviation. Expression of mRNA was normalized
to the mean of house-keeping gene 18S and alien RNA, and fold-change was determined using
the ∆∆CT method. MCT1, SMCT1 and CD147 membrane protein expression was normalized to
Na+/K+ ATPase expression. Data was analyzed in GraphPad Prism 7 using an unpaired student
T test. Differences were considered statistically significant when the p value was less than 0.05.
6.4 Results
6.4.1 MCT1 expression. mRNA and membrane expression of MCT1 following
hormone replacement is presented in Figure 6.1. MCT1 mRNA expression was significantly
lower in the 17β – estradiol treated OVX females compared to vehicle treated rats (P = 0.0155).
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CST males with testosterone treatment expressed more MCT1 mRNA compared to CST males.
This is consistent with the mRNA results in Chapter 5 (Figure 5.1A) in which MCT1 mRNA
expression was significantly higher in intact males as compared to CST males. However, the
membrane expression of MCT1 did not demonstrate any differences between the treatment
groups.
Both CST groups (testosterone and vehicle treated) had higher MCT1 mRNA expression
as compared to OVX females. In contrast, the MCT1 membrane expression was higher in OVX
females, which differs from our results in Chapter 5 where OVX females had lower MCT1
membrane expression than CST males. However, a direct comparison between the studies
cannot be made because they two groups of animals were from separate sources. In addition, the
animals are not age-matched: the 17β–estradiol treatment was for 45 days while the testosterone
treatment was for 14 days.
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Figure 6.1: Renal MCT1 mRNA and membrane expression in hormone replacement
experiments. A. Renal MCT1 mRNA expression in OVX females with or without 17β –
estradiol treatment. B. Renal MCT1 membrane protein expression OVX females with or
without 17β – estradiol treatment. C. Renal MCT1 mRNA expression in CST males with or
without testosterone treatment. D. Renal MCT1 membrane protein expression in CST males
with or without testosterone treatment. mRNA data normalized to 18s. Protein data
normalized to Na+/K+ ATPase expression. Data presented as mean ± SD. (n = 6).

6.4.2 MCT4 expression. MCT4 mRNA expression following sex hormone treatment in
OVX females and CST males is presented in Figure 6.2. MCT4 mRNA expression trended
higher in vehicle treated OVX females; however, there were no significant differences on the
mRNA expression between the vehicle treated OVX females and the 17β – estradiol treated
females. MCT4 mRNA expression was similar in CST males with and without testosterone
treatment. MCT4 protein expression was not detectable with the primary antibody used in our
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studies. MCT4 protein expression was expected to be lower than MCT1 and SMCT1 renal
expression.

Figure 6.2: MCT4 mRNA expression OVX females and CST males with and without
hormone treatment. A. MCT4 mRNA expression in OXV and OVX+ 17β – estradiol group.
B. MCT4 mRNA expression in the CST and CST+ testosterone groups. mRNA data
normalized to 18s. Data presented as mean ± SD. (n = 6 rats).
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Figure 6.3: Renal SMCT1 mRNA and membrane expression in hormone replacement
experiments. A. Renal SMCT1 mRNA expression in OVX females with or without 17β –
estradiol treatment B. Renal SMCT1 membrane protein expression OVX females with or
without 17β – estradiol treatment. C. Renal SMCT1 mRNA expression in CST males with or
without testosterone treatment. D. Renal SMCT1 membrane protein expression in CST
males with or without testosterone treatment. mRNA data normalized to 18s. Protein data
normalized to Na+/K+ ATPase expression. Data presented as mean ± SD. (n = 6 rats).

6.4.3 SMCT1 expression. mRNA and membrane expression of SMCT1 following sex
hormone replacement is presented in Figure 6.3. 17β – estradiol treated OVX females had lower
SMCT1 mRNA expression compared to the vehicle treated OVX females (P = 0.1135). In
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contrast, membrane expression of SMCT1 in both estradiol treated and vehicle treated OVX
females were similar. Testosterone treated CST males expressed significantly lower SMCT1
mRNA in the kidney compared to vehicle treated CST males (P = 0.001) (Figure 6.3C). This is
not consistent with our results in Chapter 5, which demonstrated that intact male rats had
significantly higher renal SMCT1 mRNA expression. Membrane protein expression was not
altered with testosterone treatment (Figure 6.3D). The consistent membrane expression of
SMCT1 protein among the hormone treatment groups is consistent with our observations in
Chapter 5 (Figure 5.3C).
6.4.4 CD147 expression. mRNA and membrane expression of CD147 following
hormone replacement in OVX females and CST males is presented in Figures 6.4. CD147
mRNA expression trended higher in OVX females compared to the 17β – estradiol treated OVX
females (P = 0.3187). The membrane protein expression was significantly lower when OVX
females were treated with 17β – estradiol (P = 0.0246). Consistently, mRNA expression of
CD147 in cycling females was lower compared to OVX females in Chapter 5 (Figure 5.4C). In
CST males, there were no alterations in both mRNA and protein CD147 expression between the
vehicle and testosterone treated rats. mRNA expression was consistent with the results observed
in Chapter 5; however, CST males had significantly higher CD147 membrane expression
compared to males.
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Figure 6.4: Renal CD147 mRNA and membrane expression in hormone replacement
experiments. A. Renal CD147 mRNA expression in OVX females with or without 17β –
estradiol treatment. B. Renal CD147 membrane protein expression OVX females with or
without 17β – estradiol treatment. C. Renal CD147 mRNA expression in CST males with or
without testosterone treatment. D. Renal CD147 membrane protein expression in CST males
with or without testosterone treatment. mRNA data normalized to 18s. Protein data
normalized to Na+/K+ ATPase expression. Data presented as mean ± SD. (n = 6 rats).
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6.5 Discussion
Monocarboxylate transporters are important for kidney tubule functions. MCTs are
important factors for nutrient and drug reabsorption in the kidney. Previous chapters illustrated
that MCTs, SMCTs and CD147 are expressed differently in over the female estrus cycle and
between sexes. In this chapter, the regulatory effects of individual sex hormones regulatory on
MCT/SMCT expression has been investigated. MCT1 mRNA expression was regulated by 17β
– estradiol treatment, while SMCT1 mRNA expression was regulated by both 17β – estradiol
and testosterone. MCT4 mRNA expression trended lower in 17β – estradiol treated OVX
females; however, there was a large degree of variability in OVX females. CD147 membrane
expression, but not mRNA expression, was regulated by 17β – estradiol treatment.
Kidney MCT1 mRNA expression was significantly decreased with 17β – estradiol
treatment in OVX females. This suggests that 17β – estradiol contributes to the lower mRNA
expression of MCT1. This result is not consistent with our kidney MCT1 mRNA results (Figure
5.1A). OVX groups had lower MCT1 mRNA expression than the cycling female rats. This
result indicating that 17β – estradiol is not the only factor that determines MCT1 mRNA
expression. There was no significant difference in membrane protein expression of MCT1 in the
two OVX groups (Figure 6.1B). Consistent results were observed in the previous kidney
expression study (Chapter 5; Figure 5.1C). There were no significant differences between the
four estrus stages and OVX females; however, the cycling females had lower expression
compared to OVX females. In the liver, MCT1 membrane protein was higher in OVX females
compared to metestrus females [121]. Inhibition of the ERR-alpha receptor down regulated
MCT1 expression in breast cancer baring mice [38]. Males expressed significantly higher MCT1
mRNA expression compared to CST males. The inconsistent data for testosterone treated rats

122

suggests that testosterone may not regulate of MCT1 mRNA expression. Testosterone treatment
have been shown to increase MCT1 protein and mRNA expression in skeletal muscle in intact
males [50] suggesting that CST may alter the regulatory pathways. On the other hand, MCT1
protein expression was lower in the heart with testosterone treatment indicating that there are
tissue specific regulatory pathways.
MCT4 mRNA expression data was consistent with Chapter 5 data: cycling females had
similar MCT4 mRNA expression when compared to OVX females. CST male kidney
expression data did not change compared to male rats. In the liver, we observed that MCT4
expression was lower in cycling females when compared to males and OVX females [121]
demonstrating that regulation of MCT4 mRNA expression is tissue specific.
SMCT1 mRNA expression was down regulated with treatment of testosterone, but
membrane protein expression was not significantly different between vehicle and testosterone
treated CST males. Contrasting data was observed in mice: castrated males had lower SMCT1
mRNA and protein expression compared to control and testosterone treated groups [54]. This
suggests that testosterone regulation of SMCT1 expression may be different between species.
Consistent with renal expression data in cycling females, OVX females did not demonstrated
significant differences in mRNA and protein expression in the kidney. Similar results have been
observed in mouse kidney, where ovariectomy and estradiol treatment did not alter SMCT1
mRNA and protein expression [53]. Future studies need to evaluate differences in membrane
protein expression in response to progesterone and the combination of estradiol and
progesterone.
CD147 membrane protein was significantly lower in estradiol treated OVX females and
mRNA expression trended lower in the estradiol treated group as well. This is consistent with
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the kidney expression pattern observed in cycling females indicating that 17β-estradiol plays a
vital role in membrane CD147 expression. CD147 mRNA expression was higher in ERα
knockout mice when compared to WT and ERβ knockout mice indicating estrogen was involved
in CD147 expression likely mediated by the ERα receptor [109].
Since there were no significant differences in transporter and ancillary protein expression
in the testosterone replacement experiments, further investigation is needed as the results are not
consistent with the observed expression differences described in Chapter 5. Literature data
indicates that testosterone affects MCT expression in other tissues, so requires further
investigation as to testosterones function in MCT regulation in the kidney. It is possible that the
testosterone dose in the current study was not sufficient. Previous studies utilized a testosterone
dose of 3 mg/kg/day in rat [140]. However, additional literature indicated a treatment strategy of
testosterone enanthate at 8 mg/kg once a week for 8 weeks [141]. Another study used 2.5
mg/kg/day for eight days of testosterone enanthate in mice and demonstrated altered SMCT1
expression [54]. Testosterone undecanoate was also suggested in testosterone replacement
experiments [142]. These studies suggest indicated that the treatment would result in a
physiological testosterone plasma concentration. Future studies should determine testosterone
exposure to ensure that the treatment dosage and testosterone dosage form (testosterone,
testosterone propionate, testosterone undecanoate or testosterone enanthate) reaches
physiological testosterone plasma concentrations.
In summary, MCT1 and SMCT1 mRNA expression were regulated by sex hormones.
CD147 membrane expression was regulated by17β-estrodiol. MCT4 mRNA expression was not
significantly affected by sex hormones. Ine CST males, MCT1 and CD147 membrane protein
expression was not altered with testosterone administration suggesting that the testosterone
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treatment was not sufficient. On the other hand, there is the possibility that the alterations in
monocarboxylate transporter expression observed in CST males in Chapter 5 are regulated by
other sex hormones. A higher dosage or another form of testosterone will be administered to
confirm testosterone regulation on transporter expression. It is still largely unknown if other sex
hormone such as progesterone, FSH or LH could regulate monocarboxylate transporters and
CD147 in females. In vitro studies could be conducted to identify if any of the other sex
hormones contribute to monocarboxylate transporter regulation in the kidney. Investigating
monocarboxylate transporters expression in kidney cell culture models treated with different
hormones should be conducted.
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Chapter 7: Summary and Future Directions

Proton- and sodium-dependent monocarboxylate transporters (MCTs (SLC16A) and
SMCTs (SLC5A)) transport monocarboxylates such as ketone bodies, lactate and pyruvate, as
well as drugs such as gamma-hydroxybutyric acid. CD147 acts as an ancillary protein for MCT1
and MCT4, and is involved in membrane trafficking. Previously, it has been shown that MCT
expression changes under different sex hormone conditions in skeletal muscle and Sertoli cells
[50, 51]. However, it is unknown if MCTs or CD147 demonstrates sex differences in the tissues
where MCTs play an important role in drug disposition. The purpose of the current study was to
evaluate sex and sex hormone dependent regulation of MCT1, MCT4, SMCT1 and CD147
mRNA and protein expression in drug disposition tissues including liver, intestine and kidney.
We have demonstrated sex hormone dependent regulation of MCT1 and MCT4 in the
liver. MCT1 mRNA and protein expression demonstrated differences with estrous cycle stage
and in the absence of female sex hormones, while MCT4 and CD147 membrane expression were
independent of the estrous cycle and may be regulated by testosterone.
We have for the first time demonstrated that monocarboxylate transporters and CD147
mRNA expression varied between intestinal segments; expression increased along the small
intestinal segments with highest mRNA level in ileum. MCT1, MCT4 and CD147 mRNA
expression were regulated by sex hormones in the three intestinal regions. Sex hormones
regulate mRNA expression of MCT1 and MCT4 in a regional manner, while SMCT1 expression
varies with intestinal region. SMCT1 and CD147 membrane expression did not vary over the
estrus cycle or between sexes in the duodenum and ileum. Whether intestinal MCT1 and MCT4
membrane protein expression are regulated by sex hormone is still not clear.
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Renal MCT1 and CD147 expression were altered over the estrus cycle in females and in
the absence of male and female sex hormones. MCT4 protein expression was very limited in the
kidney. Additional experiments are needed to elucidate which sex hormones regulate
monocarboxylate transporter and ancillary protein expression in the kidney. Hormone
replacement experiments demonstrated that MCT1 and SMCT1 mRNA expression was regulated
by 17β – estradiol and testosterone in the kidney. CD147 membrane expression was affected by
17β – estradiol treatment. MCT4 did not demonstrated any differences in mRNA expression,
and protein expression was not detectable.
In the current study, MCTs, SMCT1 and CD147 expression were altered under different
sex hormone conditions. The hormonal regulation was at the level of mRNA and protein
expression in tissues including intestine, liver and kidney. Many possible mechanisms for
hormonal regulation of monocarboxylate transporters have been proposed ranging from DNA
regulation to post translational modification and translocation.
Methylation of various gene promoter regions has been demonstrated to silence gene
expression [143, 144]. DNA methylation is the process in which a methyl group is added to a
nucleotide changing the activity of the DNA promoter without changing the DNA sequence.
This process normally results in the suppression of gene expression. DNA methylation of the
monocarboxylate transporter promoter region has been observed for both MCT1 and MCT4
[145, 146]. In human breast cancer cell line MDA-MB-231, the CpG island region of the MCT1
promoter was methylated and MCT1 mRNA expression was limited [145]. When treated with
demethylation reagents, the mRNA expression of MCT1 in the cell line was restored [145].
Methylation of MCT4 occurred in clear cell renal cell carcinoma patients with alteration in both
mRNA and protein expression [146]. SMCT1 in patients with head and neck cancer is also
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methylated in the promoter region and SMCT1 mRNA expression was suppressed in the human
samples [147]. Methylation could be one of the factors regulating the altered mRNA level in rat
tissues. However, due to the lack of correlation between mRNA expression and protein
expression levels, differences in protein expression under different sex hormone conditions could
be the result of other regulatory mechanisms.
Transcriptional regulation could be another mechanism regulating mRNA expression
over estrus cycle and between sexes. Previous studies demonstrated that following exercise,
AMP increases and MCT1 was stimulated due to AMP‐activated protein kinase (AMPK)
activation [148]. Others observed that the MCT1 promoter region contains transcription factor
NFAT (nuclear factor of activated T cells) binding sequences [149]. It has been shown that
activation and proliferation of T‐lymphocytes was accompanied by increased MCT1 protein
expression [149]. MCT4 could be regulated by hypoxia via promoter stimulation. The promoter
activation is mediated by hypoxia-inducible factor 1a (HIF-1a) binding to two hypoxia response
elements (HRE) [148]. This transcription factor binding site is absent in MCT1 and MCT2
promoters [150]. Currently there are limited studies evaluating the transcriptional regulation of
SMCT in both human and animal models. There are many putative mechanisms of
transcriptional regulation influencing monocarboxylate transporter expression differences
between sexes; sex steroid hormones are known binding ligands that regulate gene expression
via intracellular receptors. The mechanisms of MCTs transcriptional regulation pathways in
response to sex hormones have yet to be elucidated.
Post-transcriptional regulation represents a likely regulatory mechanism for
monocarboxylate transporters as previously discussed in the liver, intestine and kidney data
chapters. mRNA and protein expression patterns did not correlate in the same tissue sample.

128

For instance, MCT1 mRNA expression was significantly higher in male rats compared to the
female rats, but the total protein expression did not show significant increases in males. This
suggests that there is post-transcriptional modification of MCT1 (Fig 5.1A, B). It is not yet clear
how post-transcriptional regulation occurs. One research group has demonstrated that miRNA
may be contributing to this process. miRNAs are a group of short non-coding RNA that can
regulate gene expression at the post-transcriptional level. miRNAs bind to target RNA leading
to RNA degradation or inhibition of translation. miRNAs have been shown to target both human
and mouse MCT1 3′ untranslated region (UTR) [151]. Mutation of these miRNA binding sites
could abolish the miRNA binding ability [148, 151]. Further studies are required to evaluate the
detailed mechanisms of post transcriptional regulation of monocarboxylate transporters to have a
better understanding of the hormonal regulation of these transporters.
There are limitations to the current studies that could be improved in future studies.
Loading controls such as Na+/K+ ATPase and GAPDH expression could be replaced by total
protein loaded to the western blot gels. This could decrease the variability that has been
observed in Chapter 3. The variability of Na+/K+ ATPase expression among samples could be
the cause of the large inter-subject variability in western blot results. Using Stain Free gels with
total protein detection not only abolishes the variability caused by additional antibody probing
but also decreases the work load and time of conducting additional western blot. The target
protein expression could be determined via a single western blot. Further, MCT4 mRNA
expression was detectable in all tissues evaluated in this study; however, whole cell protein and
membrane protein of MCT4 was only detectable in the liver. MCT4 protein analysis was
conducted in other tissues including intestinal segments and kidney, but there were no visible
band in the western blot even with longer exposure in ChemiDoc Touch imaging system. A
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more sensitive MCT4 antibody or an alternative approach is needed to evaluate MCT4
expression.
There is still large need to investigate sex hormone dependent regulation in
monocarboxylate transporter expression in intestinal tissue. Due to the enzyme-rich environment
of the intestinal lumen, total protein and membrane protein extraction was difficult. We were
only able to quantify membrane expression in the duodenum and ileum. Alternative methods of
protein extraction should be explored to solve this limitation. MCT1 is ubiquitously expressed in
the body, but protein expression in the intestine was very limited and highly variable between
animals. mRNA expression demonstrated that MCT1 expression is increased along the small
intestine with highest expression in the ileum. Membrane expression of MCT1 was barely
detectable in the duodenum, while the ileum had higher membrane MCT1 protein expression
with a large degree of variability between animals.
An additional limitation of the present study is that we did not investigate other
monocarboxylate transporters, such as MCT2 and SMCT2. Membrane protein expression
correlates most closely with transport activity, and currently it is not possible to quantify these
isoforms due to the lack of a suitable antibody for western blot analysis. These transporters may
be regulated by sex hormones or vary between sexes. Their altered expression can also alter
drug absorption, distribution and clearance in the body.
Future work is needed to better understand sex hormone dependent regulation of
monocarboxylate transporters and their ancillary protein CD147. To confirm testosterone
regulation of monocarboxylate transporters in tissue, a higher dose or improved testosterone
form could be administered. There is still a need to elucidate if other sex hormones such as
progesterone or dihydrotestosterone are involved in the observed differences in monocarboxylate
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transporter expression. In vitro studies should be conducted to further evaluate hormonal
regulation of MCTs/SMCTs. Cell lines such as Caco2 and HK2 could be used as a screening
tool to investigate whether monocarboxylate transporters are regulated by other sex hormones.
In addition, functional studies should be conducted to evaluate transport of MCT/SMCT
substrates to determine whether transport capacity is influenced by the estrus cycle or the
removal of sex hormones in the drug disposition tissues.
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